



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07D 211/44, 211/46, 211/52, 211/58, 401/14, 417/14, 401/06, 491/10, 471/10, 405/14, 409/14, A61K 31/445	A1	(11) International Publication Number: WO 97/24324 (43) International Publication Date: 10 July 1997 (10.07.97)
(21) International Application Number: PCT/EP96/05883 (22) International Filing Date: 20 December 1996 (20.12.96) (30) Priority Data: 95203651.5 27 December 1995 (27.12.95) EP (34) Countries for which the regional or international application was filed: DE et al. (71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). (72) Inventors; and (75) Inventors/Applicants (for US only): JANSSENS, Frans, Ed- uard [BE/BE]; Tinstraat 79, B-2820 Bonheiden (BE). SOM- MEN, François, Maria [BE/BE]; Langenberg 49, B-2323 Wortel (BE). SURLERAUX, Dominique, Louis, Nestor, Ghislaine [BE/BE]; Diegemstraat 48, B-1830 Machelen (BE). VAN ROOSBROECK, Yves, Emiel, Maria [BE/BE]; Zonderschotsesteenweg 26, B-2220 Heist-opden-Berg (BE).		(81) Designated States: AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.
(54) Title: 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS		
(57) Abstract <p>The present invention concerns compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and stereochemically isomeric forms thereof, wherein n is 0, 1 or 2; m is 1 or 2, provided that if m is 2, then n is 1; p is 0, 1 or 2; -Q is -O or -NR³; X is a covalent bond or a bivalent radical of formula -O-, -S-, -NR³; R¹ is Ar¹; Ar¹C₁₋₆alkyl or di(Ar¹)C₁₋₆alkyl, wherein each C₁₋₆alkyl group is optionally substituted with hydroxy, C₁₋₆alkyloxy, oxo or a ketalized oxo substituent of formula -O-CH₂-CH₂-O- or -O-CH₂-CH₂-CH₂-O-; R² is Ar²; Ar²C₁₋₆alkyl; Het or HetC₁₋₆alkyl; R³ is hydrogen or C₁₋₆alkyl; R⁴ is hydrogen; C₁₋₆alkyl; C₁₋₆alkyloxyC₁₋₆alkyl; hydroxyC₁₋₆alkyl; carboxyl; C₁₋₆alkyloxycarbonyl or Ar³; R⁵ is hydrogen; hydroxy; Ar³; Ar³C₁₋₆alkyloxy; di(Ar³)C₁₋₆alkyloxy; Ar³C₁₋₆alkylthio; di(Ar³)C₁₋₆alkylthio; Ar³C₁₋₆alkylsulfoxy; di(Ar³)C₁₋₆alkylsulfoxy; Ar³C₁₋₆alkylsulfonyl; di(Ar³)C₁₋₆alkylsulfonyl; -NR⁷R⁸; C₁₋₆alkyl substituted with -NR⁷R⁸; or a radical of formula (a-1) or (a-2); R⁴ and R⁵ may also be taken together; R⁶ is hydrogen; hydroxy; C₁₋₆alkyloxy; C₁₋₆alkyl or Ar³C₁₋₆alkyl; Ar¹, Ar² and Ar³ are phenyl or substituted phenyl; Ar² is also naphthalenyl; and Het is an optionally substituted monocyclic or bicyclic heterocycle; as substance P antagonists; their preparation, compositions containing them and their use as a medicine.</p> <div style="text-align: center;"> </div> <div style="text-align: right;"> (I) </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

1-(1,2-DISUBSTITUTED PIPERIDINYL)-4- SUBSTITUTED PIPERIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS.

- 5 This invention concerns 1-(1,2-disubstituted piperidiny1)-4-substituted piperidine derivatives having tachykinin antagonistic activity, in particular substance P antagonistic activity, and their preparation; it further relates to compositions comprising them, as well as their use as a medicine.
- 10 Substance P is a naturally occurring neuropeptide of the tachykinin family. There are ample studies showing that substance P and other tachykinins are involved in a variety of biological actions, and therefore, play an essential role in various disorders (Regoli et al., Pharmacological Reviews 46(4), 1994, p. 551-599, "Receptors and Antagonists for Substance P and Related Peptides"). The development of tachykinin antagonists
- 15 has led to date to a series of peptide compounds of which might be anticipated that they are metabolically too labile to be employed as pharmaceutically active substances (Longmore J. et al., DN&P 8(1), February 1995, p. 5-23, "Neurokinin Receptors"). The present invention concerns nonpeptide tachykinin antagonists, in particular nonpeptide substance P antagonists, which in general are metabolically more stable,
- 20 and hence, may be more appropriate as pharmaceutically active substances.

Several nonpeptide tachykinin antagonists are disclosed in the art. For instance, EP-0,532,456-A,(Ciba-Geigy) published on March 17, 1993, discloses 1-acylpiperidine compounds, in particular 2-arylalkyl-1-arylcarbonyl-4-piperidinamine derivatives, and


25 their use as substance P antagonists.

EP-0,151,824-A(JAB 435) and EP-0,151,826-A(JAB 436) disclose structurally related 1-(1-(carbonyl or imino)-4-piperidinyl)-4-piperidinamine derivatives as histamine- and

30 serotonin antagonists.

The present compounds differ from the art compounds by their structure and by their favourable pharmacological properties.

The present invention concerns compounds of formula



the *N*-oxide forms, the pharmaceutically acceptable acid or base addition salts and stereochemically isomeric forms thereof, wherein

n is 0, 1 or 2;

m is 1 or 2, provided that if *m* is 2, then *n* is 1;

5 *p* is 0, 1 or 2;

=Q is =O or =NR³;

X is a covalent bond or a bivalent radical of formula -O-, -S-, -NR³-;

R¹ is Ar¹; Ar¹C₁₋₆alkyl or di(Ar¹)C₁₋₆alkyl, wherein each C₁₋₆alkyl group is optionally substituted with hydroxy, C₁₋₄alkyloxy, oxo or a ketalized oxo substituent of
10 formula -O-CH₂-CH₂-O- or -O-CH₂-CH₂-CH₂-O-;


R² is Ar²; Ar²C₁₋₆alkyl; Het or HetC₁₋₆alkyl;

R³ is hydrogen or C₁₋₆alkyl;

R⁴ is hydrogen; C₁₋₄alkyl; C₁₋₄alkyloxyC₁₋₄alkyl; hydroxyC₁₋₄alkyl; carboxyl; C₁₋₄alkyloxycarbonyl or Ar³;


15 R⁵ is hydrogen; hydroxy; Ar³; Ar³C₁₋₆alkyloxy; di(Ar³)C₁₋₆alkyloxy;

Ar³C₁₋₆alkylthio; di(Ar³)C₁₋₆alkylthio; Ar³C₁₋₆alkylsulfoxy; di(Ar³)C₁₋₆alkylsulfoxy; Ar³C₁₋₆alkylsulfonyl; di(Ar³)C₁₋₆alkylsulfonyl; -NR⁷R⁸; C₁₋₆alkyl substituted with -NR⁷R⁸; or a radical of formula



(a-1)

or



(a-2)

20 wherein R⁷ is hydrogen; C₁₋₆alkyl; pyridinyl or Ar³;

R⁸ is hydrogen; C₁₋₆alkyl; Ar³C₁₋₆alkyl; di(Ar³)C₁₋₆alkyl; imidazolyl substituted with Ar³, C₁₋₆alkyl or Ar³C₁₋₆alkyl; benzoxazolyl or benzothiazolyl;

R⁹ is hydrogen; hydroxy; C₁₋₆alkyl; C₁₋₆alkyloxy; Ar³; Ar³C₁₋₆alkyl; 25 di(Ar³)-C₁₋₆alkyl; amino; mono- or di(C₁₋₆alkyl)amino; imidazolyl; imidazolyl substituted with Ar³, C₁₋₆alkyl or Ar³C₁₋₆alkyl; pyrrolidinyl; piperidinyl; homopiperidinyl; morpholinyl or thiomorpholinyl;

R¹⁰ is hydrogen or C₁₋₆alkylcarbonyl;

R¹¹ is hydrogen; halo or mono-, di- or tri(halo)methyl;

30 Y is Y¹ or Y²,

wherein Y¹ is a covalent bond; C₁₋₆alkanediyl; -NR⁷- or -C₁₋₆alkanediyl-NR⁷-; or

Y^2 is -O-, provided that R^9 is other than hydroxy or C_{1-6} alkyloxy;

R^4 and R^5 may also be taken together to form a bivalent radical of formula
-O-CH₂-CH₂-O- or -C(=O)-NR³-CH₂-NR⁷-;

R^6 is hydrogen; hydroxy; C_{1-6} alkyloxy; C_{1-6} alkyl or Ar³ C_{1-6} alkyl;

5 Ar¹ is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, C_{1-4} alkyl, halo C_{1-4} alkyl, cyano, aminocarbonyl, C_{1-4} alkyloxy or halo C_{1-4} alkyloxy;

Ar² is naphthalenyl; phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from hydroxy, halo, cyano, nitro, amino, mono- or
10 di(C_{1-4} alkyl)amino, C_{1-4} alkyl, halo C_{1-4} alkyl, C_{1-4} alkyloxy, halo C_{1-4} alkyloxy, carboxyl, C_{1-4} alkyloxycarbonyl, aminocarbonyl and mono- or di(C_{1-4} alkyl)amino-carbonyl;

Ar³ is phenyl or phenyl substituted with 1, 2 or 3 substituents selected from halo, hydroxy, amino, nitro, aminocarbonyl, C_{1-6} alkyl, halo C_{1-6} alkyl or C_{1-6} alkyloxy; and

15 Het is a monocyclic heterocycle selected from pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocycle selected from quinolinyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl and benzothieryl; each monocyclic and bicyclic
20 heterocycle may optionally be substituted on a carbon atom by 1 or 2 substituents selected from halo, C_{1-4} alkyl or mono-, di- or tri(halo)methyl.

The heterocycles in the definition of Het are preferably connected to the rest of the molecule, *i.e.* X. -C(=Q)- or C_{1-6} alkyl, by a carbon atom.

25

As used in the foregoing definitions and hereinafter, halo is generic to fluoro, chloro, bromo and iodo; C_{1-4} alkyl defines straight and branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as, for example, methyl, ethyl, propyl, butyl, 1-methylethyl, 2-methylpropyl and the like; C_{1-6} alkyl is meant to include

30 C_{1-4} alkyl and the higher homologues thereof having 5 to 6 carbon atoms such as, for example, pentyl, 2-methylbutyl, hexyl, 2-methylpentyl and the like; C_{1-4} alkanediyl defines bivalent straight and branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as, for example, methylene, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl, and the like; C_{1-6} alkanediyl is meant to include C_{1-4} alkanediyl and the
35 higher homologues thereof having from 5 to 6 carbon atoms such as, for example, 1,5-pentanediyl, 1,6-hexanediyl and the like.

As used in the foregoing definitions and hereinafter, haloC₁₋₄alkyl is defined as mono- or polyhalosubstituted C₁₋₄alkyl, in particular C₁₋₄alkyl substituted with 1 to 6 halogen atoms, more in particular difluoro- or trifluoromethyl.

5 The pharmaceutically acceptable addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I) are able to form. Said salts can conveniently be obtained by treating the base form of the compounds of formula (I) with appropriate acids such as, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydro-
10 bromic acid; sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, *p*-toluenesulfonic, cyclamic, salicylic, *p*-aminosalicylic, pamoic and the like acids.

15 The pharmaceutically acceptable addition salts as mentioned hereinabove are also meant to comprise the therapeutically active non-toxic base, in particular, the metal or amine addition salt forms which the compounds of formula (I) are able to form. Said salts can conveniently be obtained by treating the compounds of formula (I) containing
20 acidic hydrogen atoms with appropriate organic and inorganic bases such as, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. the benzathine, *N*-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.

25 Conversely said salt forms can be converted by treatment with an appropriate base or acid into the free acid or base form.

30 The term addition salt as used hereinabove also comprises the solvates which the compounds of formula (I) as well as the salts thereof, are able to form. Such solvates are for example hydrates, alcoholates and the like.

For isolation and purification purposes, it is also possible to use pharmaceutically unacceptable salts. Only the pharmaceutically acceptable, non-toxic salts are used
35 therapeutically and those salts are therefore preferred.

The term "stereochemically isomeric forms" as used hereinbefore defines all the possible isomeric as well as conformational forms which the compounds of formula (I)

may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture, more in particular the racemic mixture, of all possible stereochemically and conformationally isomeric forms, said mixtures containing all diastereomers, enantiomers and/or conformers of the basic molecular structure. More
5 in particular, stereogenic centers may have the R- or S-configuration; substituents on bivalent cyclic saturated radicals may have either the *cis*- or *trans*-configuration; $>C=NR^3$ and C_{3-6} alkenyl radicals may have the E- or Z-configuration. For the compounds having two stereogenic centers, the relative stereodescriptors R^* and S^* are used in accordance with the Chemical Abstracts rules (Chemical Substance Name
10 Selection Manual (CA), 1982 Edition, Vol. III, Chapter 20). All stereochemically isomeric forms of the compounds of formula (I) both in pure form or mixtures thereof are intended to be embraced within the scope of the present invention.

Some of the compounds of formula (I) may also exist in their tautomeric form. Such
15 forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention. For instance, compounds of formula (I) wherein X is -NH- and =Q is =O or R^5 is a radical of formula (a-1) or (a-2), may exist in their corresponding tautomeric form.

20 The N-oxide forms of the compounds of formula (I) are meant to comprise those compounds of formula (I) wherein one or several nitrogen atoms are oxidized to the so-called N-oxide, particularly those N-oxides wherein one or more of the piperidine-nitrogens are N-oxidized.

25 Whenever used hereinafter, the term "compounds of formula (I)" is meant to also include their N-oxide forms, their pharmaceutically acceptable addition salts, and their stereochemically isomeric forms.

A special group of compounds are those compounds of formula (I) wherein R^8 is
30 hydrogen; C_{1-6} alkyl; Ar^3C_{1-6} alkyl; $di(Ar^3)C_{1-6}$ alkyl; benzoxazolyl or benzothiazolyl; R^9 is hydrogen; hydroxy; C_{1-6} alkyl; C_{1-6} alkyloxy; Ar^3 ; Ar^3C_{1-6} alkyl; $di(Ar^3)C_{1-6}$ alkyl; amino; mono- or $di(C_{1-6}$ alkyl)amino; pyrrolidinyl; piperidinyl; homo-piperidinyl; morpholinyl or thiomorpholinyl; and Het is a monocyclic heterocycle selected from pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl,
35 thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocycle selected from quinolinyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl and benzothieryl; each monocyclic and

bicyclic heterocycle may optionally be substituted on a carbon atom by 1 or 2 substituents selected from halo, C₁₋₄alkyl or mono-, di- or tri(halo)methyl.

A first group of interesting compounds consists of those compounds of formula (I)

5 wherein one or more of the following restrictions apply :

a) R¹ is Ar¹C₁₋₆alkyl; or

b) R² is pyrimidinyl; naphthalenyl; pyrrolyl; furanyl; quinoxalinyll; pyridinyl; indolyl; benzofuranyl; benzothienyl; thiazolyl; thienyl; pyrazinyl; each of said monocyclic and bicyclic heterocycles may optionally be substituted on a carbon atom by 1 or 2 substituents selected from halo, C₁₋₄alkyl or mono-, di- or tri(halo)methyl; or R² is phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, cyano, C₁₋₄alkyl, C₁₋₄alkyloxy, haloC₁₋₄alkyloxy, C₁₋₄alkyloxycarbonyl and haloC₁₋₄alkyl, in particular, selected from methyl and trifluoromethyl; or phenyl-C₁₋₆alkyl wherein phenyl in said phenylC₁₋₆alkyl is optionally substituted with 1, 2 or 3 substituents selected from halo and C₁₋₄alkyloxy; or

c) n is 1; or

d) m is 1; or

e) =Q is =O; or

f) X is a covalent bond or a bivalent radical of formula -S- or -NR³-, in particular a covalent bond.

A second group of interesting compounds consists of those compounds of formula (I) wherein p is 1; R⁴ is hydrogen; Ar³ or C₁₋₄alkyloxyC₁₋₄alkyl; R⁵ is hydroxy; Ar³, di(Ar³)C₁₋₆alkyloxy; -NR⁷R⁸; C₁₋₆alkyl substituted with -NR⁷R⁸; or a radical of formula (a-1) or (a-2); R⁴ and R⁵ are taken together to form a bivalent radical of formula -O-CH₂-CH₂-O- or -C(=O)-NR⁷-CH₂-NR⁷-; R⁶ is hydrogen.

Of special interest are those compounds of formula (I) wherein R¹ is Ar¹C₁₋₆alkyl, R² is phenyl substituted with 2 substituents selected from methyl or trifluoromethyl, X is a covalent bond and =Q is =O.

Further of special interest are those compounds of formula (I) wherein n and m are 1 and p is 1.

A particular group of compounds consists of those compounds of formula (I) wherein R¹ is phenylmethyl; R² is phenyl substituted with 2 substituents selected from methyl or trifluoromethyl; n and m are 1; X is a covalent bond; and =Q is =O.

Another particular group of compounds consists of those compounds of formula (I) wherein p is 1; R⁴ is hydrogen; C₁₋₄alkyloxyC₁₋₄alkyl, phenyl or phenyl substituted with halo; R⁵ is phenyl; amino substituted with phenyl or substituted imidazolyl; or phenyl substituted with halo; or R⁵ is a radical of formula (a-1) wherein Y is Y¹ or Y² wherein Y¹ is a covalent bond, -NR⁷- or -CH₂-NR⁷-; wherein R⁷ is hydrogen or phenyl optionally substituted with halo; Y² is -O-; R⁹ is C₁₋₆alkyl, C₁₋₆alkyloxy, pyrrolidinyl, phenylC₁₋₆alkyl, imidazolyl substituted with phenylC₁₋₆alkyl or Ar³; or R⁵ is a radical of formula (a-2) wherein R¹⁰ is hydrogen or C₁₋₆alkylcarbonyl; R¹¹ is hydrogen; or R⁴ and R⁵ are taken together to form a bivalent radical of formula -C(=O)-NR³-CH₂-NR⁷- wherein each R⁷ independently is selected from hydrogen or phenyl; and R⁶ is hydrogen.

Preferred compounds are those compounds of formula (I) wherein R¹ is phenylmethyl; R² is phenyl substituted with 2 substituents selected from methyl or trifluoromethyl; n, m and p are 1; X is a covalent bond; =Q is =O; R⁴ is hydrogen, phenyl or phenyl substituted with halo; R⁵ is phenyl, phenyl substituted with halo; or R⁵ is a radical of formula (a-1) wherein Y is Y¹ or Y² wherein Y¹ is a covalent bond, -NR⁷- or -CH₂-NR⁷-; wherein R⁷ is hydrogen or phenyl optionally substituted with halo; Y² is -O-; R⁹ is C₁₋₆alkyl, C₁₋₆alkyloxy, pyrrolidinyl, phenylC₁₋₆alkyl or Ar³; or R⁵ is a radical of formula (a-2) wherein R¹⁰ is hydrogen or C₁₋₆alkylcarbonyl; R¹¹ is hydrogen; or R⁴ and R⁵ are taken together to form a bivalent radical of formula -C(=O)-NH-CH₂-NR⁷- wherein R⁷ is phenyl; and R⁶ is hydrogen.

Most preferred are those compounds selected from

1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-(2,3-dihydro-2-oxo-1*H*-benzimidazol-1-yl)-1-piperidinyl]-2-(phenylmethyl)piperidine;

1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-[4-phenyl-4-(1-pyrrolidinylcarbonyl)-1-piperidinyl]piperidine;


N-[[1-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-4-phenyl-4-piperidinyl]methyl]acetamide;

1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl]-2-(phenylmethyl)piperidine;


1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-phenyl-4-(1-pyrrolidinylcarbonyl)-1-piperidinyl]-2-[[4-(trifluoromethyl)phenyl]methyl]piperidine; and

1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-difluorophenyl)methyl]-4-[4-phenyl-4-(1-pyrrolidinylcarbonyl)-1-piperidinyl]piperidine; and the pharmaceutically acceptable acid addition salts and the stereo isomeric forms thereof.


The compounds of formula (I) can be prepared by reductively *N*-alkylating an intermediate of formula (III) with an intermediate of formula (II). Said reductive *N*-alkylation may be performed in a reaction-inert solvent such as, for example, dichloromethane, ethanol, toluene or a mixture thereof, and in the presence of a reducing agent such as, for example, a borohydride, e.g. sodium borohydride, sodium cyano-borohydride or triacetoxy borohydride. In case a borohydride is used as a reducing agent, it may be convenient to use a catalyst such as, for example, titanium(IV) isopropylate as described in J. Org. Chem, 1990, 55, 2552-2554. Using said catalyst may also result in an improved *cis/trans* ratio in favour of the *trans* isomer. It may also be convenient to use hydrogen as a reducing agent in combination with a suitable catalyst such as, for example, palladium-on-charcoal or platinum-on-charcoal. In case hydrogen is used as reducing agent, it may be advantageous to add a dehydrating agent to the reaction mixture such as, for example, aluminium *tert*-butoxide. In order to prevent the undesired further hydrogenation of certain functional groups in the reactants and the reaction products, it may also be advantageous to add an appropriate catalyst-poison to the reaction mixture, e.g., thiophene or quinoline-sulphur. Stirring and optionally elevated temperatures and/or pressure may enhance the rate of the reaction.



- 20 In this and the following preparations, the reaction products may be isolated from the reaction medium and, if necessary, further purified according to methodologies generally known in the art such as, for example, extraction, crystallization, trituration and chromatography.
- 25 The compounds of formula (I) can also be prepared by reacting an intermediate of formula (IV) wherein W¹ is an appropriate leaving group such as, for example, a halogen, e.g. chloro or bromo, or a sulfonyloxy leaving group, e.g. methanesulfonyloxy or benzenesulfonyloxy, with an intermediate of formula (V). The reaction can be performed in a reaction-inert solvent such as, for example, a chlorinated hydrocarbon, e.g. dichloromethane, an alcohol, e.g. ethanol, or a ketone, e.g. methyl isobutylketone, and in the presence of a suitable base such as, for example, sodium carbonate, sodium hydrogen carbonate or triethylamine. Stirring may enhance the rate of the reaction. The reaction may conveniently be carried out at a temperature ranging between RT and reflux temperature.



- The compounds of formula (I) may also be prepared by reacting a piperidinone derivative of formula (VI) with an appropriate organometallic reagent of formula (VII) wherein R^{4'} is the same as R⁴ but other than hydrogen and M is an organometallic part such as, e.g. -MgBr, yielding compounds of formula (I) wherein R⁵ is -OH, said compounds being represented by formula (I-a).



As outlined below, compounds of formula (I) may be converted into each other using art-known transformations.

For instance, compounds of formula (I) wherein R⁵ is -OH may be converted into compounds of formula (I) wherein R⁵ is Ar³C₁₋₆alkyloxy, di(Ar³)C₁₋₆alkyloxy or a radical of formula (a-1) wherein Y is O.

Also, compounds of formula (I) wherein R⁵ is -NR⁷H may be converted into compounds of formula (I) wherein R⁵ is -NR⁷R⁸, R⁸ being other than hydrogen; or wherein R⁵ is a radical of formula (a-1) wherein Y is -NR⁷.

Further, compounds of formula (I) wherein R⁵ is a radical of formula (a-2) wherein R¹⁰ is hydrogen may be converted into compounds of formula (I) wherein R⁵ is a radical of formula (a-2) wherein R¹⁰ is a C₁₋₆alkylcarbonyl.

The compounds of formula (I) may also be converted to the corresponding *N*-oxide forms following art-known procedures for converting a trivalent nitrogen into its *N*-oxide form. Said *N*-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboxoperoxy acid or halo substituted benzenecarboxoperoxy acid, e.g. 3-chlorobenzenecarboxoperoxy acid, peroxyalkanoic acids, e.g. peroxyacetic acid,


alkylhydroperoxides, e.g. *tert*-butyl hydroperoxide. Suitable solvents are, for example, water, lower alkanols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.

5

The starting materials and some of the intermediates are known compounds and are commercially available or may be prepared according to conventional reaction procedures generally known in the art. For example, intermediates of formula (III), (IV), (VII) and (XI) may be prepared according to art-known procedures.

10

Intermediates of formula (II) may be prepared by condensing an intermediate of formula (IV) with an intermediate of formula (VIII) analogous to the procedure described in EP-0,532,456-A.




15

The preparation of intermediates of formula (VIII) is also described in EP-0,532,456-A. However, intermediates of formula (VIII) wherein R^1 is optionally substituted $\text{Ar}^1\text{C}_{1-6}\text{alkyl}$ or $\text{di}(\text{Ar}^1)\text{C}_{1-6}\text{alkyl}$, said R^1 being represented by $-\text{CH}(\text{R}^{1a})_2$ and said intermediates being represented by formula (VIII-a), may also be prepared as depicted in scheme 1.

20


Scheme 1



In scheme 1, the intermediates of formula (IX-b) may be prepared by reacting an intermediate of formula (IX-a) with an aldehyde or a ketone of formula (X). The C₁₋₆alkyl-

carbamate moiety in the intermediates of formula (IX-b) may be converted into a fused oxazolone which in turn may be reduced to an intermediate of formula (IX-d). Said intermediate (IX-d) may in turn be deprotected, thus forming an intermediate of formula (VIII-a). Subsequently, intermediates of formula (VIII-a) may be reacted with an intermediate of formula (IV) to prepare intermediates of formula (II) wherein R^1 is defined as $-\text{CH}(R^{1a})_2$, said intermediates being represented by formula (II-a). The reactions performed in scheme 1 may all be conducted following conventional methods that are generally known in the art.


- Intermediates of formula (V) may suitably be prepared by reacting an intermediate of formula (VIII-1), being a protected intermediate of formula (VIII) with a protecting group P^1 such as, for example, a C_{1-6} alkyloxycarbonyl group, with an intermediate of formula (III) according to the previously described reductive N -alkylation procedure, and subsequently deprotecting the thus formed intermediate.



In particular, intermediates of formula (V) wherein R^1 is $-\text{CH}(R^{1a})_2$, said intermediates being represented by formula (V-a), may be prepared as is depicted in scheme 2.


20

Scheme 2



The ketalized intermediate of formula (IX-c) may be transformed to the corresponding ketone of formula (IX-e) which subsequently may be reductively aminated with a pyrrolidine, piperidine- or homopiperidine derivative of formula (III). The thus obtained intermediate may then be reduced with a suitable reducing agent to an intermediate of formula (V-a).

Piperidinone derivatives of formula (VI) may be prepared by reacting an intermediate of formula (II) with an intermediate of formula (XI), according to the previously described *N*-alkylation procedure, followed by deprotection.



Pure stereochemically isomeric forms of the compounds of formula (I) may be obtained by the application of art-known procedures. Diastereomers may be separated by physical methods such as selective crystallization and chromatographic techniques, e.g., counter-current distribution, liquid chromatography and the like.

The compounds of formula (I) as prepared in the hereinabove described processes are generally racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures. The racemic compounds of formula (I) which are sufficiently basic or acidic may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid, respectively chiral base. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali or acid. An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography, in particular liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.

The compounds of formula (I) have valuable pharmacological properties in that they interact with tachykinin receptors and they antagonize tachykinin-induced effects, especially substance P-induced effects, both *in vivo* and *in vitro* and are thus of use in

the treatment of tachykinin-mediated diseases, and in particular in substance P-mediated diseases.

5 Tachykinins, also referred to as neurokinins, are a family of peptides among which substance P (SP), neurokinin A (NKA), neurokinin B (NKB) and neuropeptide K (NPK) may be identified. They are naturally occurring in mammals, including human beings, and are distributed throughout the central and peripheral nervous system, where they act as neurotransmitters or neuromodulators. Their actions are mediated through several subtypes of receptors, such as, for example, NK₁, NK₂ and NK₃ receptors.

10 Substance P displays highest affinity for NK₁ receptors, whereas NKA preferentially binds to NK₂ receptors and NKB preferentially binds to NK₃ receptors. However, the selectivity of these tachykinins is relatively poor and under physiological conditions the action of any of these tachykinins might be mediated by activation of more than one receptor type.

15 Substance P and other neurokinins are involved in a variety of biological actions such as pain transmission (nociception), neurogenic inflammation, smooth muscle contraction, plasma protein extravasation, vasodilation, secretion, mast cell degranulation, and also in activation of the immune system. A number of diseases are

20 deemed to be engendered by activation of neurokinin receptors, in particular the NK₁ receptor, by excessive release of substance P and other neurokinins in particular cells such as cells in the neuronal plexi of the gastrointestinal tract, unmyelinated primary sensory afferent neurons, sympathetic and parasympathetic neurons and nonneuronal cell types (DN&P 8(1), February 1995, p. 5-23, "Neurokinin Receptors" by Longmore

25 J. et al.; Pharmacological Reviews 46(4), 1994, p. 551-599, "Receptors and Antagonists for Substance P and Related Peptides" by Regoli et al.).

The compounds of the present invention are potent inhibitors of neurokinin-mediated effects, in particular those mediated via the NK₁ receptor, and may therefore be

30 described as tachykinin antagonists, especially as substance P antagonists, as indicated *in vitro* by the antagonism of substance P-induced relaxation of pig coronary arteries which is described hereinafter. The binding affinity of the present compounds for the human, guinea-pig and gerbil neurokinin receptors may be determined *in vitro* in a receptor binding test using ³H-substance P as radioligand. The subject compounds

35 also show substance-P antagonistic activity *in vivo* as may be evidenced by, for instance, the antagonism of substance P-induced plasma extravasation in guinea-pigs, or the antagonism of drug-induced emesis in ferrets (Watson et al., Br. J. Pharmacol. 115, 84-94, 1995).

In view of their capability to antagonize the actions of tachykinins by blocking the tachykinin receptors, and in particular antagonizing the actions of substance P by blocking the NK₁ receptor, the subject compounds are useful in the prophylactic and

- 5 therapeutic treatment of tachykinin-mediated diseases such as, for example,
- pain, in particular traumatic pain such as postoperative pain; traumatic avulsion pain such as brachial plexus; chronic pain such as arthritic pain such as occurring in osteo-
10 , rheumatoid or psoriatic arthritis; neuropathic pain such as post-herpetic neuralgia, trigeminal neuralgia, segmental or intercostal neuralgia, fibromyalgia, causalgia, peripheral neuropathy, diabetic neuropathy, chemotherapy-induced neuropathy, AIDS-related neuropathy, occipital neuralgia, geniculate neuralgia, glossopharyngeal neuralgia, reflex sympathetic dystrophy, phantom limb pain; various forms of headache such as migraine, acute or chronic tension headache, temperomandibular pain, maxillary sinus pain, cluster headache; odontalgia; cancer pain; pain of visceral
15 origin; gastrointestinal pain; nerve entrapment pain; sport's injury pain; dysmennorrhoea; menstrual pain; meningitis; arachnoiditis; musculoskeletal pain; low back pain e.g. spinal stenosis; prolapsed disc; sciatica; angina; ankylosing spondylitis; gout; burns; scar pain; itch; and thalamic pain such as post stroke thalamic pain;
 - 20 - respiratory and inflammatory diseases, in particular inflammation in asthma, influenza, chronic bronchitis and rheumatoid arthritis; inflammatory diseases of the gastrointestinal tract such as Crohn's disease, ulcerative colitis, inflammatory bowel disease and non-steroidal anti-inflammatory drug induced damage; inflammatory diseases of the skin such as herpes and eczema; inflammatory diseases of the
25 bladder such as cystitis and urge incontinence; and eye and dental inflammation;
 - emesis, i.e. nausea, retching and vomiting, including acute emesis, delayed emesis and anticipatory emesis, no matter how emesis is induced, for example, emesis may be induced by drugs such as cancer chemotherapeutic agents such as alkylating agents, e.g. cyclophosphamide, carmustine, lomustine and chlorambucil; cytotoxic
30 antibiotics, e.g. dactinomycin, doxorubicin, mitomycin-C and bleomycin; anti-metabolites, e.g. cytarabine, methotrexate and 5-fluorouracil; vinca alkaloids, e.g. etoposide, vinblastine and vincristine; and others such as cisplatin, dacarbazine, procarbazine and hydroxyurea; and combinations thereof; radiation sickness; radiation therapy, e.g. irradiation of the thorax or abdomen, such as in the treatment
35 of cancer; poisons; toxins such as toxins caused by metabolic disorders or by infection, e.g. gastritis, or released during bacterial or viral gastrointestinal infection; pregnancy; vestibular disorders, such as motion sickness, vertigo, dizziness and

Meniere's disease; post-operative sickness; gastrointestinal obstruction; reduced gastrointestinal motility; visceral pain, e.g. myocardial infarction or peritonitis; migraine; increased intracranial pressure; decreased intracranial pressure (e.g. altitude sickness); opioid analgesics, such as morphine; and gastro-oesophageal reflux disease, acid indigestion, over-indulgence of food or drink, acid stomach, sour stomach, waterbrash/regurgitation, heartburn, such as episodic heartburn, nocturnal heartburn, and meal-induced heartburn and dyspepsia;

- central nervous system disorders, in particular psychoses such as schizophrenia, mania, dementia or other cognitive disorders e.g. Alzheimer's disease; anxiety; AIDS-related dementia; diabetic neuropathy; multiple sclerosis; depression; Parkinson's disease; and dependence on drugs or substances of abuse;
- allergic disorders, in particular allergic disorders of the skin such as urticaria, and allergic disorders of the airways such as rhinitis;
- gastrointestinal disorders, such as irritable bowel syndrome;
- skin disorders, such as psoriasis, pruritis and sunburn;
- vasospastic diseases, such as angina, vascular headache and Reynaud's disease;
- cerebral ischaemia, such as cerebral vasospasm following subarachnoid haemorrhage
- stroke, epilepsie, head trauma, spinal cord trauma and ischemic neuronal damage;
- fibrosing and collagen diseases, such as scleroderma and eosinophilic fascioliasis;
- disorders related to immune enhancement or suppression, such as systemic lupus erythematosus;
- rheumatic diseases, such as fibrositis;
- neoplastic disorders;
- cell proliferation; and
- cough.

The compounds of the present invention have a favourable metabolic stability and exhibit good oral availability. They also have an advantageous onset and duration of action. The compounds of formula (I) also have the ability to penetrate the central nervous system as may be demonstrated *in vivo* by their inhibitory effect on the change in behaviour induced by intracerebroventricular-applied substance P in the gerbil.

In view of the utility of the compounds of formula (I), there is provided a method of treating warm-blooded animals, including humans, suffering from tachykinin-mediated diseases as mentioned hereinabove, in particular, pain, emesis or asthma. Said method comprises the systemic administration of an effective tachykinin antagonizing amount of a compound of formula (I), a *N*-oxide form, a pharmaceutically acceptable addition

salt or a possible stereoisomeric form thereof, to warm-blooded animals, including humans. Hence, the use of a compound of formula (I) as a medicine is provided, and in particular a medicine to treat pain, emesis or asthma.

- 5 For ease of administration, the subject compounds may be formulated into various pharmaceutical forms for administration purposes. To prepare the pharmaceutical compositions of this invention, a therapeutically effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which may take a wide
- 10 variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols,
- 15 oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid
- 20 pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable solutions containing
- 25 compounds of formula (I) may be formulated in an oil for prolonged action. Appropriate oils for this purpose are, for example, peanut oil, sesame oil, cottonseed oil, corn oil, soy bean oil, synthetic glycerol esters of long chain fatty acids and mixtures of these and other oils. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In
- 30 the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wettable agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause any significant deleterious effects on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired
- 35 compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on or as an ointment. Acid or base addition salts of compounds of formula (I) due to their increased water solubility over the

corresponding base or acid form, are obviously more suitable in the preparation of aqueous compositions.

5 In order to enhance the solubility and/or the stability of the compounds of formula (I) in pharmaceutical compositions, it can be advantageous to employ α -, β - or γ -cyclodextrins or their derivatives, in particular hydroxyalkyl substituted cyclodextrins, e.g. 2-hydroxypropyl- β -cyclodextrin. Also co-solvents such as alcohols may improve the solubility and/or the stability of the compounds of formula (I) in pharmaceutical compositions.

10 It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity
15 of active ingredient calculated to produce the desired therapeutic effect, in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

20 Those of skill in the treatment of tachykinin mediated diseases could determine the effective therapeutic daily amount from the test results presented hereinafter. An effective therapeutic daily amount would be from about 0.001 mg/kg to about 40 mg/kg body weight, more preferably from about 0.01 mg/kg to about 5 mg/kg body
25 weight. It may be appropriate to administer the therapeutically effective dose once daily or as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 0.05 mg to 500 mg, and in particular, 0.5 mg to 50 mg of active ingredient per unit dosage form.

30 The exact dosage and frequency of administration depends on the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight and general physical condition of the particular patient as well as other medication the patient may be taking, as is well known to those skilled in
35 the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated patient and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. The effective daily amount ranges mentioned hereinabove are therefore only guidelines.

The following examples are intended to illustrate and not to limit the scope of the present invention.

5 Experimental Part

Hereinafter "THF" means tetrahydrofuran, "DIPE" means diisopropylether, "RT" means room temperature and "DMF" means *N,N*-dimethylformamide. Of some compounds of formula (I) the absolute stereochemical configuration was not experimentally determined. In those cases the stereochemically isomeric form which was first isolated is designated as "A" and the second as "B", without further reference to the actual stereochemical configuration.

Preparation of the intermediate compounds

Example A1

- 15 a) A mixture of 1,1-dimethylethyl 1,4-dioxo-8-azaspiro[4.5]-8-carboxylate (0.1 mol) in diethylether (150ml) and *N,N,N',N'*-tetramethyl-ethylenediamine (33.2ml) was cooled on a 2-propanol/CO₂ bath under a N₂ flow. *Sec.* butyllithium (1.3 M; 0.11 mol) was added dropwise at a temperature below -60°C and the mixture was stirred for 3 hours. A mixture of 3,5-(difluoro)benzaldehyde (0.12 mol) in diethylether (75ml) was added dropwise. The mixture was stirred slowly overnight and allowed to warm to RT. The mixture was decomposed with water and separated into its layers. The aqueous layer was extracted with CH₂Cl₂. The combined organic layer was dried, filtered and the solvent was evaporated, yielding 38.5g of 1,1-dimethylethyl 7-[(3,4-difluorophenyl)-hydroxymethyl]-1,4-dioxo-8-azaspiro[4.5]-8-carboxylate (intermediate 10).
- 20 b) A mixture of intermediate 10 (0.1 mol) and 2-methyl-2-propanol, potassium salt (1g) in toluene (200ml) was stirred and refluxed for 2 hours. The solvent was evaporated and the residue was taken up in CH₂Cl₂/water. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 98/2). The pure fractions were collected and the solvent was evaporated. The residue was suspended in petroleum ether and the precipitate was filtered off and dried, yielding 10g (32%) of (±)-1'-(3,4-difluorophenyl)tetrahydrospiro[1,3-dioxolan-2,7'(1'H)-[3H]-oxazolo[3,4-a]pyridin]-3-one (intermediate 11).
- 25 c) A mixture of intermediate 11 (0.032 mol) in CH₃OH (250ml) was hydrogenated at 50°C with palladium on activated carbon (10%; 2g). After uptake of hydrogen, the catalyst was filtered off and the filtrate was evaporated, yielding 9g (100%) of 7-[(3,4-difluorophenyl)methyl]-1,4-dioxo-8-azaspiro[4.5]decane (intermediate 12).
- 30
- 35

d) A mixture of intermediate 12 (0.032 mol) in HCl, (6N; 90ml) was stirred at 75°C, then cooled. CH₂Cl₂ was added and the mixture was alkalized with NaOH at a temperature below 20°C. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was dried, yielding 7.2g of 2-[(3,4-difluorophenyl)methyl]-4-piperidinone (intermediate 13).

In a similar way as described in procedure d) were prepared :

(±)-2-(phenylmethyl)-4-piperidinone (intermediate 1);

(±)-*trans*-1-(3,5-dimethylbenzoyl)-4-(4-oxo-1-piperidinyl)-2-(phenylmethyl)piperidine (intermediate 2, mp. 108.4°C);

(±)-*cis*-1-(3,5-dimethylbenzoyl)-4-(4-oxo-1-piperidinyl)-2-(phenylmethyl)piperidine (intermediate 3); and

2-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-4-piperidinone (intermediate 14).

e) A mixture of intermediate 1 in CH₂Cl₂, 3,5-dimethylbenzoyl chloride (7.4 g) and triethylamine (11 ml) was stirred overnight at RT. Dilute NaOH was added. The organic layer was separated, dried, filtered and the solvent evaporated. The residue was crystallized from DIPE yielding 7.44 g (58%) of (±)-1-(3,5)-dimethylbenzoyl-2-(phenylmethyl)-4-piperidinone (intermediate 4).

In a similar way as described in procedure e) were prepared :

(±)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-[[4-(trifluoromethyl)phenyl]methyl]-4-piperidinone (intermediate 15);

(±)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-difluorophenyl)methyl]-4-piperidinone (intermediate 16); and

(±)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-4-piperidinone (intermediate 17).

Example A2

Alternative to the procedure sequence as described in example A1.a) through A1.c), the following procedure may be used. *Sec*-butyllithium (0.63 mol) was added at -78°C under N₂ flow to a solution of 1,1-dimethylethyl 1,4-dioxo-8-azaspiro[4.5]-8-carboxylate (0.57 mol) and *N,N,N',N'*-tetramethylethylenediamine (1.14 mol) in (C₂H₅)₂O (1000 ml). One hour after complete addition, a mixture of 3-(trifluoromethyl)benzaldehyde (0.57 mol) in (C₂H₅)₂O (200 ml) was added. The mixture was allowed to warm to RT and then stirred at RT for 16 hours. The solvent was evaporated. A mixture of 2-methyl-2-propanol, potassium salt (0.2 mol) in toluene (500 ml) was added. The mixture was stirred at 80°C for 5 hours. The solvent was evaporated. The residue was heated with a saturated NH₄Cl solution and extracted with CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was

evaporated. The residue was suspended in DIPE, filtered off and dried. This fraction was dissolved in CH₃OH (250 ml) and the mixture was hydrogenated with palladium on activated carbon (10%, 3 g) as a catalyst. After uptake of hydrogen, the catalyst was filtered off and the filtrate was evaporated. The residue was purified over silica gel on a glass filter (eluent: CH₂Cl₂/CH₃OH 95/5). The pure fractions were collected and the solvent was evaporated. This fraction was dissolved in HCl (6N, 100 ml) and CH₃OH (100 ml) and the mixture was stirred at 50°C for 8 hours. The organic solvent was evaporated. The concentrate was washed with a saturated K₂CO₃ solution and extracted with CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent : CH₂Cl₂/CH₃OH 95/5). The pure fractions were collected and the solvent was evaporated, yielding 48.5 g (70 %) of (±)-2-[[4-(trifluoromethyl)phenyl]methyl]-4-piperidinone (intermediate 18).

15 Example A3

A mixture of (±)-8-*tert*-butoxycarbonyl-7-(phenylmethyl)-1,4-dioxo-8-azaspiro[4.5]-decane (33.34 g) in HCl, (6 N; 250 ml) was stirred at 70°C for 1 hour 30 minutes. The mixture was cooled, CH₂Cl₂ (100 ml) was added and the mixture was alkalized with NaOH while cooling to RT. The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂. Triethylamine (20.2 g), followed by 3,5-bis(trifluoromethyl)benzoyl chloride (27.7 g) dissolved in CH₂Cl₂ were added and the mixture was stirred for 2 hours. Water was added and the layers were separated. The organic layer was dried, filtered and evaporated. The residue was crystallized from DIPE, the precipitate was filtered off and dried. The mother layer was evaporated and the residue was crystallized from DIPE. The precipitate was filtered off and dried. The two solid fractions were taken up in water and CH₂Cl₂. NaOH was added and the mixture was extracted. The organic layer was dried, filtered off and evaporated, yielding 16.14g (38%) of (±)-1-[3,5-bis-(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinone (intermediate 5, mp. 102.5 °C).

30

Example A4

Di-*tert*-butyl dicarbonate (21.8 g) was added to a mixture of intermediate 1 (17 g) in CH₂Cl₂ (500 ml) and the mixture was stirred at RT for 48 hours. The mixture was evaporated, the residue was taken up in water and toluene and the organic layer was separated. The aqueous layer was extracted again with toluene. The combined organic layers were dried, filtered and evaporated, yielding 38 g (100%) of (±)-1,1-dimethyl-ethyl 4-oxo-2-(phenylmethyl)-1-piperidinecarboxylate (intermediate 6).

35

Example A5

Hydrochloric acid in 2-propanol (10 ml) was added to a mixture of (±)-1,1-dimethylethyl (*cis+trans*)-4-[4-(2,3-dihydro-2-oxo-1*H*-benzimidazol-1-yl)-1-piperidinyl]-2-(phenylmethyl)-1-piperidinecarboxylate (12 g) in CH₃OH (100 ml) and the mixture was stirred and refluxed for 2 hours 30 minutes. The solvent was evaporated and the residue was taken up in CH₂Cl₂ and water with diluted NaOH. The organic layer was separated, washed with water, dried, filtered and evaporated. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/ (CH₃OH/NH₃) 93/7). A first fraction was collected and evaporated, yielding 2.1 g (±)-*cis*-1,3-dihydro-1-[1-[2-(phenylmethyl)-4-piperidinyl]-4-piperidinyl]-2*H*-benzimidazol-2-one (intermediate 7). A second fraction was collected and evaporated, yielding 0.9 g (±)-*trans*-1,3-dihydro-1-[1-[2-(phenylmethyl)-4-piperidinyl]-4-piperidinyl]-2*H*-benzimidazol-2-one (intermediate 8).

Example A6

4-(Methoxymethyl)-*N*-phenyl-1-(phenylmethyl)-4-piperidinamine (15 g) was hydrogenated in CH₃OH (250 ml) with palladium on activated carbon (10%; 3 g) as a catalyst. After uptake of H₂, the catalyst was filtered off. The filtrate was evaporated and the residue was dissolved in 2-propanol (300 ml) and converted into the hydrobromic acid salt (1:2) with hydrobromic acid in acetic acid. This mixture was stirred for 1 hour. DIPE (200 ml) was added and the resulting mixture was stirred for 1 hour. The precipitate was filtered off, washed with DIPE and recrystallized from ethanol/DIPE 3/1. The crystals were filtered off and dried, yielding 12.9 g (70%) of 4-(methoxymethyl)-*N*-phenyl-4-piperidinamine dihydrobromide (intermediate 9, mp. 220.0 °C).

Example A7

a) A mixture of (±)-1,1-dimethylethyl 4-oxo-2-(phenylmethyl)-1-piperidine carboxylate (0.1 mol) and *N*-(4-phenyl-4-piperidinyl)acetamide (0.1 mol) in 2-propanol (500ml) was hydrogenated at 50°C with platinum (4g) as a catalyst in the presence of titanium(IV)isopropoxide (28.5g) and thiophene (4%; 1ml). After uptake of hydrogen, the catalyst was filtered off and the filtrate was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 97/3). The pure fractions were collected and the solvent was evaporated, yielding 40g (74.1%) of (±)-1,1-dimethylethyl 4-[4-(acetylamino)-4-phenyl-1-piperidinyl]-2-(phenylmethyl)-1-piperidinecarboxylate (intermediate 19).

b) A mixture of intermediate 19 (0.081 mol) in CH₃OH (300ml) and 2-propanol in HCl (30ml) was stirred and refluxed for 2 hours. The solvent was evaporated. The residue

was taken up in water/DIPE and the mixture was separated into its layers. The aqueous layer was alkalized with NaOH and CH₂Cl₂ was added. The combined organic layer was washed with water, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/ (CH₃OH /NH₃) 95/5). Two pure fractions were collected and their solvents were evaporated, yielding 3 g of fraction 1, 2 g fraction 2 and 2.5g of (±)-*N*-[1-[2-(phenylmethyl)-4-piperidiny]-4-phenyl-4-piperidiny]acetamide (intermediate 20). Fraction 1 was dissolved in 2-propanol and converted into the hydrochloric acid salt (1:2) with HCl / 2-propanol. The precipitate was filtered off and dried, yielding 0.24g (±)-*cis-N*-[1-[2-(phenylmethyl)-4-piperidiny]-4-phenyl-4-piperidiny]acetamide dihydrochloride dihydrate (intermediate 21). Intermediate 20 was repurified by column chromatography over silica gel (eluent: CH₂Cl₂/ (CH₃OH /NH₃) 95/5). The pure fractions were collected and the solvent was evaporated. The residue was dissolved in 2-propanol and converted into the hydrochloric acid salt (1:2) with HCl/2-propanol. The precipitate was filtered off and dried, yielding 0.44 g of (±)-*trans-N*-[4-phenyl-1-[2-(phenylmethyl)-4-piperidiny]-4-piperidiny]acetamide dihydrochloride dihydrate (intermediate 22). Less pure fractions (20g) were repurified by HPLC over silica gel (eluent: CH₂Cl₂/ (CH₃OH /NH₃) 95/5). Two pure fraction groups were collected and their solvent was evaporated, yielding 6.5g (±)-*cis-N*-[4-phenyl-1-[2-(phenylmethyl)-4-piperidiny]-4-piperidiny]acetamide (intermediate 23) and 7.2 g (±)-*trans-N*-[1-[2-(phenylmethyl)-4-piperidiny]-4-phenyl-4-piperidiny]acetamide (intermediate 24). In a similar way were prepared :
(±)-*trans*-1-[[1-[4-phenyl-2-(phenylmethyl)-4-piperidiny]-4-piperidiny]carbonyl]-pyrrolidine (E)-2-butenedioate(1:2) (intermediate 25);
(±)-*cis*-1-[[1-[4-phenyl-2-(phenylmethyl)-4-piperidiny]-4-piperidiny]carbonyl]-pyrrolidine (E)-2-butenedioate(1:2) (intermediate 26);
(±)-*cis*-1-[[1-[4-phenyl-2-(phenylmethyl)-4-piperidiny]-4-piperidiny]carbonyl]-pyrrolidine (intermediate 27); and
(±)-*trans*-1-[[1-[4-phenyl-2-(phenylmethyl)-4-piperidiny]-4-piperidiny]carbonyl]-pyrrolidine (intermediate 28).

Example A8

a) 4-Oxo-1-piperidinecarboxylic acid 1,1-dimethylethyl ester (0.053 mol), 1-[(4-fluorophenyl)methyl]-1*H*-imidazol-2-amine and titanium(IV)isopropoxyde (0.055 mol) were stirred at 50°C for 2 hours. Ethanol (350ml) and sodium borohydride (0.53 mol) were added. The mixture was stirred at RT overnight and water was added. The mixture was filtered over decalite, washed with ethanol/ CH₂Cl₂ and the solvent was

evaporated. The residue was taken up in CH_2Cl_2 , dried, filtered and the solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent: CH_2Cl_2 / CH_3OH 100/0, 99/1, 98/2, 97/3, 96/4 and 94/6). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from DIPE and the precipitate was filtered off and dried, yielding 11.3g (57%) of 1,1-dimethylethyl 4-[[1-[(4-fluorophenyl)methyl]-1*H*-imidazol-2-yl]amino]-1-piperidinecarboxylate (intermediate 29).

b) A mixture of intermediate 29 (0.026 mol) in a solution of HCl in 2 propanol (15ml) and CH_3OH (110ml) was stirred and refluxed for 1 hour. The solvent was evaporated. The residue was taken up in $\text{H}_2\text{O}/\text{CH}_2\text{Cl}_2$. The mixture was alkalized with NaOH. The organic layer was separated, dried, filtered and the solvent was evaporated, yielding 4.95g (69%) of *N*-[1-[(4-fluorophenyl)methyl]-1*H*-imidazol-2-yl]-4-piperidinamine (intermediate 30).

15 Preparation of the compounds of formula (I)

Example B1

a) Titanium(IV)isopropoxide (18 g) was added to 4-hydroxypiperidine (5 g) and intermediate 4 (16 g) in CH_2Cl_2 (25 ml) and the mixture was stirred at RT for 3 hours. Sodium cyanoborohydride (2 g) dissolved in ethanol (50 ml) was added and the mixture was stirred at RT overnight. Water (50 ml) and CH_2Cl_2 (1000 ml) were added, the mixture was filtered through celite, washed with CH_2Cl_2 and the filtrate was evaporated. The residue was purified by column chromatography over silica gel (eluent : $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 96/4). The pure fractions were collected and evaporated, yielding 8.3 g (41 %) of (\pm)-*cis*-1-(3,5-dimethylbenzoyl)-4-(4-hydroxy-1-piperidinyl)-2-(phenylmethyl)piperidine (compound 30) and 4.1 g (20 %) of (\pm)-*trans*-1-(3,5-dimethylbenzoyl)-4-(4-hydroxy-1-piperidinyl)-2-(phenylmethyl)piperidine (compound 31).

b) A mixture of intermediate 5 (0.01 mol), 4-[[1-[(4-fluorophenyl)methyl]-1*H*-benzimidazol-2-yl]methyl]-4-piperidinol (0.01 mol) and titanium(IV)isopropoxide (0.011 mol) in 2-propanol (5ml) was stirred at 40°C for 2.5 hours and then cooled. Ethanol (100ml) and sodiumborohydride were added. The mixture was heated to 50°C and sodiumborohydride (0.05 mol) was added over a 3 hour period. The mixture was stirred at RT overnight. Water (30ml) was added and the mixture was stirred for 30 seconds and then filtered over decalite. The decalite was washed with CH_2Cl_2 , dried and filtered, to give mixture 1. The filtrate was evaporated and the residue was taken up in CH_2Cl_2 , dried and filtered, to give mixture 2. Mixture 1 and 2 were combined and the solvent was evaporated. The residue was purified by column chromatography

over RP 18 (eluent: ammoniumacetate (0.5% in H₂O)/CH₃OH/ CH₃CN 70/15/15 to CH₃OH/ CH₃CN 50/50 to CH₃CN 100%). Two pure fractions were collected and their solvents were evaporated, yielding 2.9 g of (±)-*cis*-1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-[[1-[(4-fluorophenyl)methyl]-1*H*-benzimidazol-2-yl)methyl]-4-hydroxy-1-

5 piperidiny]-2-(phenylmethyl)piperidine (39%) (compound 74) and 3 g(40%) of (±)-*trans*-1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-[[1-[(4-fluorophenyl)-methyl]-1*H*-benzimidazol-2-yl)methyl]-4-hydroxy-1-piperidiny]-2-(phenylmethyl)-piperidine (compound 75).

c) A solution of intermediate 15 (0.01 mol), 1-(4-phenyl-4-piperidinylcarbonyl)-pyrrolidine hydrochloride (0.01 mol) and triethylamine (0.015 mol) in THF (10 ml) and titanium(IV)isopropoxide (3.72ml) was stirred at RT for 4 hours. Ethanol (10ml) and sodium cyanoborohydride (0.01 mol) were added. The mixture was stirred for a few hours. Ice and ethanol (10ml) were added and the mixture was stirred at RT for 30 minutes and then filtered over decalite. The solvent was evaporated and the residue

15 extracted with CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by HPLC over silica gel (eluent : CH₂Cl₂/CH₃OH 95/5). Two pure fractions were collected and their solvents were evaporated. The residue was crystallized from DIPE. The precipitate was filtered off and dried, yielding 4.07g of (±)-*cis*-1-[3,5-bis(trifluoromethyl)-benzoyl]-4-[4-phenyl-4-

20 (1-pyrrolidinylcarbonyl)-1-piperidiny]-2-[[4-(trifluoromethyl)-phenyl]methyl]-piperidine (55%) (compound 111) and 1.3 g of (±)-*trans*-1-[3,5-bis(trifluoromethyl)-benzoyl]-4-[4-phenyl-4-(1-pyrrolidinylcarbonyl)-1-piperidiny]-2-[[4-(trifluoromethyl)-phenyl]methyl]-piperidine (18%) (compound 112).

25 Example B2

A mixture of intermediate 2 (14.6) and benzenemethanamine (3.9 g) in CH₃OH (250 ml) and thiophene (4%; 1 ml) was hydrogenated at 50°C overnight with palladium on activated carbon (10%; 2 g) as a catalyst. The catalyst was filtered off and the filtrate was evaporated. The residue was taken up in CH₃OH (250 ml) and

30 hydrogenated further at RT overnight with palladium on activated carbon (10%; 2 g) as a catalyst. After uptake of hydrogen, the catalyst was filtered off and the filtrate was evaporated. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/(CH₃OH/NH₃) 95/5). The pure fractions were collected and evaporated, yielding 9.1 g (62%) of (±)-*trans*-4-(4-amino-1-piperidiny)-1-

35 (3,5-dimethylbenzoyl)-2-(phenylmethyl)piperidine (compound 22).

Example B3

A mixture of intermediate 2 (2 g) and 2-methoxybenzylamine (0.7 g) in CH₃OH

(150 ml) was hydrogenated overnight at 50 °C with palladium on activated carbon (10 %; 1 g) as a catalyst in the presence of thiophene (4 % solution; 1 ml). After uptake of hydrogen, the catalyst was filtered off and the filtrate was evaporated. The residue was purified by HPLC over silica gel (eluent: from 100 % CH₂Cl₂ to 100% CH₂Cl₂/CH₃OH (90/10) over 20 minutes at 125 ml/minute). The desired fractions were collected and the solvent was evaporated. The residue was dried, yielding 0.1 g (3.9%) of (±)-*trans*-1-(3,5-dimethylbenzoyl)-4-[4-[(2-methoxyphenyl)methyl]-amino]-1-piperidiny]-2-(phenylmethyl)piperidine (compound 35, mp. 71.2 °C).

10 Example B4

A mixture of compound 3 (2 g), phenylethyl methanesulfonate (1 g) and sodium carbonate (0.75 g) in ethanol (50 ml) was stirred and refluxed overnight. The solvent was evaporated, the residue was taken up in water and extracted with CH₂Cl₂. The organic layer was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH 95/5). The pure fractions were collected and the solvent evaporated. The residue was dried, yielding 0.61 g (24 %) of (±)-*trans*-1-(3,5-dimethylbenzoyl)-4-[4-[(2-phenylethyl)amino]-1-piperidiny]-2-(phenylmethyl)piperidine (compound 27, mp. 67.8 °C).

20 Example B5

3,5-Dichlorobenzoyl chloride (1 g) was added to a mixture of compound 31 (2 g) and triethylamine (0.5 g) in CH₂Cl₂ (25 ml) and the mixture was stirred at RT for 1 hour. The mixture was washed with water. The organic layer was dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH 97/3). The pure fractions were collected and their solvent evaporated. The residue was dried, yielding 0.34 g (11.7 %) of (±)-*trans*-1-[1-(3,5-dimethylbenzoyl)-2-(phenylmethyl)-4-piperidiny]-4-piperidiny 3,5-dichlorobenzoate (compound 33, mp. 83.3 °C).

30 Example B6

Using the same reaction procedure as described in example B5, 3,5-bis(trifluoromethyl)benzoyl chloride was reacted with intermediate 8 to form (±)-*trans*-1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-(2,3-dihydro-2-oxo-1*H*-benzimidazol-1-yl)-1-piperidiny]-2-(phenylmethyl)piperidine (compound 43, mp. 156.1 °C).

35

Example B7

Using the same reaction procedure as described in example B6, 3,5-dimethylbenzoyl

chloride was reacted with compound 22 to form (\pm)-*trans*-N-[1-[1-(3,5-dimethylbenzoyl)-2-(phenylmethyl)-4-piperidinyl]-4-piperidinyl]-3,5-dimethylbenzamide (compound 21, mp. 120.1°C).

5 **Example B8**

Using the same reaction procedure as described in example B6, propionyl chloride was reacted with (\pm)-*cis*-4-[4-(2,3-dihydro-2-oxo-1*H*-benzimidazol-1-yl)-1-piperidinyl]-1-(3,5-dimethylbenzoyl)-2-(phenylmethyl)piperidine to form (\pm)-*cis*-1-[1-[1-(3,5-dimethylbenzoyl)-2-(phenyl-methyl)-4-piperidinyl]-4-piperidinyl]-1,3-dihydro-3-(1-oxopropyl)-2*H*-benzimidazol-2-one (compound 34).

10 **Example B9**

Magnesium turnings (0.25 g) in THF were stirred and refluxed. 2-Bromoanisole (0.9 g) dissolved in THF (15 ml) was added dropwise and the mixture was stirred and refluxed for 3 hours. Intermediate 2 (2.7 g) dissolved in THF (15 ml) was added and the mixture was stirred and refluxed overnight. The mixture was washed with water, the layers were separated and the aqueous layer was extracted with CH₂Cl₂. The combined organic layers were dried, filtered and evaporated. The residue was dried and further purified by HPLC (eluent : CH₂Cl₂/CH₃OH 100/0 to 98/2). The pure fractions were collected and evaporated. The residue was suspended in water/ CH₃OH/CH₃CN 30/40/40, filtered off and dried, yielding 0.2 g (5.8 %) of (\pm)-*trans*-1-(3,5-dimethylbenzoyl)-4-[4-hydroxy-4-(2-methoxyphenyl)-1-piperidinyl]-2-(phenyl-methyl)-piperidine (compound 17, mp. 213.1°C).

25 **Example B10**

A solution of (\pm)-ethyl *cis*-1-[1-(3,5-dimethylbenzoyl)-2-(phenylmethyl)-4-piperidinyl]-4-phenyl-4-piperidinecarboxylate (2.96 g) in NaOH (20 ml) and dioxane (50 ml) was stirred and refluxed for 30 hours. The mixture was evaporated and HCl (1*N*; 20 ml) was added. The precipitate was filtered off, water (100 ml) and CH₂Cl₂ (10 ml) were added and filtered again. The precipitate was taken up in water, heated, cooled, filtered off and dried. The product was purified by HPLC (eluent : ammoniumacetate and CH₃CN). The pure fractions were collected, evaporated and dried, yielding 1.09 g (39%) of (\pm)-*cis*-1-[1-(3,5-dimethylbenzoyl)-2-(phenylmethyl)-4-piperidinyl]-4-phenyl-4-piperidinecarboxylic acid (compound 38, mp. 259.1°C).

35

Example B11

A mixture of (\pm)-*cis*-4-(4-amino-1-piperidinyl)-1-(3,5-dimethylbenzoyl)-2-(phenyl-methyl)piperidine (4 g) and 2*H*,3*H*-1,3-benzoxazine-2,6-dione (1.6 g) in DMF (100 ml)

was stirred and heated at 80°C for 4 hours. The mixture was evaporated and the residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH 98/2). The pure fractions were collected and evaporated. The residue was dried, yielding 1.34 g (25.5%) of (±)-*cis*-2-amino-*N*-[1-[1-(3,5-dimethylbenzoyl)-2-(phenylmethyl)-4-piperidiny]-4-piperidiny]benzamide (compound 24, mp. 121.1 °C).

Example B12

2,4-dimethyl-5-thiazoic acid(0.080 g) and 1*H*-benzotriazol-1-ol (0.060 g) were added to intermediate 22 (0.100 g) in CH₂Cl₂ (5 ml). The mixture was stirred and cooled on an ice-bath, under N₂ flow. Triethylamine was added dropwise. A solution of (CH₃)₂-N-(CH₂)₃-N=N-CH₂-CH₃ (0.080 g) in CH₂Cl₂ (5 ml) was added dropwise and the reaction mixture was allowed to warm to RT, under N₂. The reaction mixture was stirred overnight. Then, the compound was isolated and purified by column chromatography (eluent: (0.5% ammoniumacetate in H₂O)/CH₃OH/ CH₃CN 70/15/15 upgrading to 0/0/100). The desired fractions were collected and the solvent was evaporated, yielding 0.070 g of (±)-*trans*-*N*-[1-[1-[(2,4-dimethyl-5-thiazolyl)carbonyl]-2-(phenylmethyl)-4-piperidiny]-4-phenyl-4-piperidiny]acetamide (compound 121)

Example B13

A mixture of (±)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinone (0.018 mol), intermediate 30 (0.018 mol) and titanium(IV)isopropoxide (0.018 mol) in 2-propanol (150 ml) was hydrogenated at 50°C with platinum on activated carbon 5% (2g) as a catalyst in the presence of a thiophene solution (1ml). After uptake of hydrogen, the catalyst was filtered off and the filtrate was evaporated. The residue was taken up in H₂O and CH₂Cl₂, filtered over decalite and washed several times with H₂O. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by HPLC over silica gel (eluent: CH₂Cl₂/ CH₃OH/(CH₃OH/NH₃) 95/4.5/0.5). Two pure fractions were collected and their solvents were evaporated. The residue was dried, yielding 1.02 g of (±)-*cis*-1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-[[1-[(4-fluorophenyl)methyl]-1*H*-imidazol-2-yl]amino]-1-piperidiny]-2-(phenylmethyl)-piperidine (compound 72) and 0.77 g (6%) of (±)-*trans*-1-[3,5-bis(trifluoromethyl)-benzoyl]-4-[4-[[1-[(4-fluorophenyl)methyl]-1*H*-imidazol-2-yl]amino]-1-piperidiny]-2-(phenylmethyl)piperidine (compound 73).


Example B14






A mixture of intermediate 23 (0.0025 mol) and 3,5-di(trifluoromethyl)-1-isocyanato-benzene (0.0025 mol) in CH₂Cl₂ (25ml) was stirred at RT overnight. The solvent was evaporated and the residue was crystallized from CH₃CN. The precipitate was filtered











off and dried, yielding: 0.88g (54%) of (\pm)-*cis*-4-[4-(acetylamino)-4-phenyl-1-piperidinyl]-*N*-[3,5-bis(trifluoromethyl)phenyl]-2-(phenylmethyl)-1-piperidine-carboxamide (compound 127).











- 5 The following tables list compounds of formula (I) as prepared according to one of the above examples (Ex.).










Table 1



Co. No.	Ex. No.	R ¹²	R ⁴	R ⁵	Physical data
1	B2	CH ₃	4-chlorophenyl	-OH	(\pm)- <i>cis</i> ; mp. 162.1°C
2	B1a	CH ₃	phenyl	-NH-CO-CH ₃	(\pm)- <i>cis</i> ; mp. 131.4°C
3	B1a	CH ₃	phenyl	-NH-CO-CH ₃	(\pm)- <i>trans</i> ; mp. 128.5°C
4	B2	CH ₃	H		(\pm)- <i>cis</i> ; mp. 145.5°C
5	B2	CH ₃	H		(\pm)- <i>trans</i> ; mp. 161.9°C
6	B2	CH ₃	-CH ₂ -O-CH ₃	aminophenyl	(\pm)- <i>cis</i> ; mp. 144.3°C
6a	B2	CH ₃	-CH ₂ -O-CH ₃	aminophenyl	(\pm)- <i>trans</i>
7	B1a	CH ₃	H		(\pm)- <i>cis</i> ; mp. 71.3°C
8	B1a	CH ₃	H	-O-CH(C ₆ H ₅) ₂	(\pm)- <i>trans</i> ; mp. 85.8°C
9	B1a	CH ₃	phenyl	phenyl	(A)
10	B1a	CH ₃	phenyl	phenyl	(B)
11	B1a	CH ₃	4-chlorophenyl	-C(=O)-CH ₂ -C ₆ H ₅	(A)
12	B1a	CH ₃	H		(A)
13	B1a	CH ₃	H		(B)
14	B1a	CH ₃	phenyl	-CH ₂ -NH-CO-CH ₃	(A)
15	B1a	CH ₃	phenyl	-CH ₂ -NH-CO-CH ₃	(B)
16	B9	CH ₃	3-methoxyphenyl	OH	(\pm)- <i>cis</i> ; mp. 102.1°C

Co. No.	Ex. No.	R ¹²	R ⁴	R ⁵	Physical data
17	B9	CH ₃	3-methoxyphenyl	OH	(±)- <i>trans</i> ; mp. 213.1°C
18	B7	CH ₃	H		(±)- <i>cis</i> ; mp. 130.1°C
19	B7	CH ₃	H		(±)- <i>trans</i> ; mp. 131.5°C
20	B7	CH ₃	H		(±)- <i>cis</i> ; mp. 100.2°C
21	B7	CH ₃	H		(±)- <i>trans</i> ; mp. 120.1°C
22	B2	CH ₃	H	-NH ₂	(±)- <i>trans</i> ;
23	B2	CH ₃	H	-NH ₂	(±)- <i>cis</i>
24	B11	CH ₃	H		(±)- <i>cis</i> ; mp. 121.1°C
25	B11	CH ₃	H		(±)- <i>trans</i> ; mp. 256.6°C
26	B4	CH ₃	H	-NH-(CH ₂) ₂ -C ₆ H ₅	(±)- <i>cis</i> ; mp. 224.5°C
27	B4	CH ₃	H	-NH-(CH ₂) ₂ -C ₆ H ₅	(±)- <i>trans</i> ; mp. 67.8°C
28	B1a	CH ₃	H		(±)- <i>cis</i> ; mp. 88.3°C
29	B1a	CH ₃	H		(±)- <i>trans</i> ; mp. 91.6°C
30	B1a	CH ₃	H	OH	(±)- <i>cis</i> ;
31	B1a	CH ₃	H	OH	(±)- <i>trans</i> ;
32	B5	CH ₃	H		(±)- <i>cis</i> ; mp. 68.2°C
33	B5	CH ₃	H		(±) <i>trans</i> ; mp. 83.3°C

Co. No.	Ex. No.	R ¹²	R ⁴	R ⁵	Physical data
34	B8	CH ₃	H		(±)- <i>cis</i>
35	B3	CH ₃	H		(±)- <i>trans</i> ; mp. 71.2°C
36	B2	CH ₃	phenyl	-C(=O)-O-C ₂ H ₅	(±)- <i>cis</i> ; mp. 133.6°C
37	B2	CH ₃	phenyl	-C(=O)-O-C ₂ H ₅	(±)- <i>trans</i> ;
38	B10	CH ₃	phenyl	-C(=O)-OH	(±)- <i>cis</i> ; mp. 259.1°C
39	B1a	CF ₃	4-chlorophenyl	OH	(A)
40	B1a	CF ₃	4-chlorophenyl	OH	(B)
41	B1a	CF ₃	H		(±)
42	B6	CF ₃	H		(±)- <i>cis</i> ; mp. 159.2°C
43	B6	CF ₃	H		(±)- <i>trans</i> ; mp. 156.1°C
44	B1a	CF ₃	H	-O-CH(C ₆ H ₅) ₂	(A)
45	B1a	CF ₃	H	-O-CH(C ₆ H ₅) ₂	(B)
46	B1a	CF ₃	phenyl		(±)-(cis+trans)
47	B1a	CF ₃	phenyl		(±)- <i>cis</i> ; mp. 127.0°C
48	B1a	CF ₃	phenyl		(±)- <i>trans</i> ; mp. 137.8°C
49	B1a	CF ₃	phenyl	-CH ₂ -NH-CO-CH ₃	(±)
50	B1a	CF ₃	phenyl	phenyl	(A)
51	B1a	CF ₃	phenyl	phenyl	(B)
52	B1a	CF ₃	H		(A)
53	B1a	CF ₃	H		(B)

Co. No.	Ex. No.	R ¹²	R ⁴	R ⁵	Physical data
54	B1a	CF ₃	H		(A)
55	B1a	CF ₃	H		(B)
60	B1a	CF ₃	H		(±)-cis
61	B1a	CF ₃	H		(±)-trans
62	B6	F	phenyl	-NH-C(=O)-CH ₃	(±)-cis
63	B6	Cl	phenyl	-NH-C(=O)-CH ₃	(±)-cis
64	B6	Cl	phenyl	-C(=O)-O-C ₂ H ₅	(±)-cis
65	B6	H	phenyl	-NH-C(=O)-CH ₃	(±)-cis
66	B6	Cl	phenyl	-C(=O)-O-C ₂ H ₅	(±)-trans
67	B6	H	phenyl	-C(=O)-O-C ₂ H ₅	(±)-trans
68	B6	F	phenyl	-C(=O)-O-C ₂ H ₅	(±)-trans
69	B8	CH ₃	CH ₂ -O-CH ₃		(±)-cis
70	B6	F	phenyl		(±)-cis
71	B8	CH ₃	CH ₂ -O-CH ₃		(±)-cis
72	B13	CF ₃	H		(±)-cis
73	B13	CF ₃	H		(±)-trans





Co. No.	Ex. No.	R ¹²	R ⁴	R ⁵	Physical data
74	B1b	CF ₃	OH		(±)- <i>cis</i>
75	B1b	CF ₃	OH		(±)- <i>trans</i>
76	B1b	CF ₃	phenyl	-C(=O)-O-C ₂ H ₅	(±)- <i>trans</i>
77	B1b	CF ₃	phenyl	-C(=O)-O-C ₂ H ₅	(±)- <i>cis</i>
78	B1b	CF ₃	phenyl	-NH-C(=O)-CH ₃	(±)- <i>cis</i>
79	B1b	CF ₃	phenyl	-NH-C(=O)-CH ₃	(±)- <i>trans</i>

Table 2



Co.No.	Ex. No.	R ¹²	-R ⁴ -R ⁵ -	Physical data
56	B2	CH ₃	-O-CH ₂ -CH ₂ -O-	(±)- <i>cis</i> ; mp. 65.6°C
57	B2	CH ₃	-O-CH ₂ -CH ₂ -O-	(±)- <i>trans</i> ; mp. 70.8°C
58	B1a	CF ₃	-C(=O)-NH-CH ₂ -N(phenyl)-	(±)- <i>cis</i>
59	B1a	CF ₃	-C(=O)-NH-CH ₂ -N(phenyl)-	(±)- <i>trans</i>
80	B1a	CF ₃	-C(=O)-N(CH ₃)-CH ₂ -N(phenyl)-	(±)- <i>cis</i>
81	B1a	CF ₃	-C(=O)-N(CH ₃)-CH ₂ -N(phenyl)-	(±)- <i>trans</i>

Table 3




Co.No.	Ex. No.	R ¹³	X*	R ²	Physical data
82	B12	H	d.b.		(±)- <i>trans</i>
83	B6	H	d.b.	3-(trifluoro)phenyl	(±)- <i>cis</i>
84	B12	H	d.b.		(±)- <i>trans</i>
85	B12	H	d.b.		(±)- <i>cis</i>
86	B12	H	d.b.		(±)- <i>cis</i>
87	B12	H	d.b.		(±)- <i>cis</i>
88	B1b	F	d.b.	3,5-di(trifluoromethyl)phenyl	(±)- <i>cis</i>
89	B6	H	d.b.		(±)- <i>trans</i>
90	B6	H	d.b.		(±)- <i>trans</i>
91	B6	H	d.b.	3-methylphenyl	(±)- <i>trans</i>
92	B6	H	d.b.	3-cyanophenyl	(±)- <i>trans</i>
93	B6	H	d.b.	2,4,6-trimethylphenyl	(±)- <i>trans</i>
94	B6	H	d.b.	2-naphtalenyl	(±)- <i>trans</i>
95	B6	H	d.b.	2-quinoxaliny	(±)- <i>trans</i>
96	B6	H	d.b.	2,6-dichloro-4-pyridiny	(±)- <i>trans</i>
97	B6	H	d.b.	2-furanyl	(±)- <i>trans</i>
98	B6	H	d.b.	(CH ₃) ₂ -CH-	(±)- <i>trans</i>
99	B6	H	d.b.	1-methyl-2-pyrrolyl	(±)- <i>trans</i>
100	B6	H	d.b.	2-furanyl	(±)- <i>cis</i>

Co.No.	Ex. No.	R ¹³	X*	R ²	Physical data
101	B6	H	d.b.	2-quinoxaliny	(±)- <i>cis</i>
102	B6	H	d.b.	2,6-dichloro-4-pyridiny	(±)- <i>cis</i>
103	B6	H	-S-	phenyl	(±)- <i>cis</i>


* d.b. means direct bond

Table 4







Co.No.	Ex. No.	R ¹⁴	R ¹⁵	R ¹⁶	R ¹	Physical data
104	B12	H	H	H		(±)- <i>cis</i>
105	B12	H	H	H		(±)- <i>cis</i>
106	B12	H	H	H		(±)- <i>trans</i>
107	B12	H	H	H		(±)- <i>trans</i>
108	B12	H	H	H		(±)- <i>trans</i>
109	B1b	F	H	CF ₃	3,5-di(trifluoromethyl)phenyl	(±)- <i>cis</i>
110	B1b	F	H	CF ₃	3,5-di(trifluoromethyl)phenyl	(±)- <i>trans</i>
111	B1c	H	H	CF ₃	3,5-di(trifluoromethyl)phenyl	(±)- <i>cis</i>
112	B1c	H	H	CF ₃	3,5-di(trifluoromethyl)phenyl	(±)- <i>trans</i>
113	B1b	H	F	F	3,5-di(trifluoromethyl)phenyl	(±)- <i>cis</i>
114	B1b	H	F	F	3,5-di(trifluoromethyl)phenyl	(±)- <i>trans</i>
115	B6	H	Cl	Cl	3,5-di(trifluoromethyl)phenyl	(±)- <i>cis</i>
116	B6	H	Cl	Cl	3,5-di(trifluoromethyl)phenyl	(±)- <i>trans</i>
117	B6	H	H	H	(CH ₃) ₂ -CH-	(±)- <i>cis</i>
118	B6	H	H	H	3-(trifluoromethyl)phenyl	(±)- <i>trans</i>

Table 5



Co.No.	Ex. No.	R ¹⁴	R ¹⁵	R ¹⁶	X*	R ²	Physical data
119	B12	H	H	H	d.b.		(±)- <i>cis</i>
120	B12	H	H	H	d.b.		(±)- <i>cis</i>
121	B12	H	H	H	d.b.		(±)- <i>trans</i>
122	B6	H	H	H	d.b.	3-cyanophenyl	(±)- <i>trans</i>
123	B6	H	H	H	d.b.	3-methylphenyl	(±)- <i>cis</i>
124	B1b	F	H	CF ₃	d.b.	3,5-di(trifluoromethyl)phenyl	(±)- <i>cis</i>
125	B1b	F	H	CF ₃	d.b.	3,5-di(trifluoromethyl)phenyl	(±)- <i>trans</i>
126	B6	H	H	H	d.b.	3-(trifluoromethyl)phenyl	(±)- <i>cis</i>
127	B14	H	H	H	d.b.	3,5-di(trifluoromethyl)phenyl	(±)- <i>cis</i>
128	B1b	H	F	F	d.b.	3,5-di(trifluoromethyl)phenyl	(±)- <i>trans</i>
129	B1b	H	F	F	d.b.	3,5-di(trifluoromethyl)phenyl	(±)- <i>cis</i>
130	B6	H	H	H	d.b.	2,4,6-trimethylphenyl	(±)- <i>cis</i>
131	B6	H	H	H	d.b.	2,4,6-trimethoxyphenyl	(±)- <i>cis</i>
132	B6	H	H	H	d.b.	4-(trifluoromethoxy)phenyl	(±)- <i>cis</i>
133	B6	H	H	H	d.b.	2-thienyl	(±)- <i>cis</i>
134	B6	H	H	H	d.b.	2-quinolinyl	(±)- <i>cis</i>
135	B6	H	H	H	d.b.		(±)- <i>cis</i>
136	B6	H	H	H	d.b.	2,4-dichlorophenyl	(±)- <i>trans</i>
137	B6	H	H	H	d.b.	1-methyl-2-pyrrolyl	(±)- <i>trans</i>
138	B6	H	H	H	d.b.	2-naphtalenyl	(±)- <i>trans</i>
139	B6	H	H	H	d.b.	2-quinoxaliny	(±)- <i>trans</i>

Co.No.	Ex. No.	R ¹⁴	R ¹⁵	R ¹⁶	X*	R ²	Physical data
140	B6	H	H	H	d.b.	2-naphtalenyl	(±)- <i>trans</i>
141	B6	H	H	H	d.b.	2-quinoxalinylnyl	(±)- <i>cis</i>
142	B6	H	H	H	d.b.		(±)- <i>cis</i>
143	B6	H	H	H	d.b.	2-furanyl	(±)- <i>cis</i>
144	B6	H	H	H	d.b.	2,6-dichloro-4-pyridinyl	(±)- <i>trans</i>
145	B6	H	H	H	d.b.	2-furanyl	(±)- <i>trans</i>
146	B6	H	H	H	d.b.		(±)- <i>cis</i>
147	B6	H	H	H	d.b.		(±)- <i>cis</i>
148	B6	H	H	H	d.b.	2-naphtalenyl	(±)- <i>cis</i>
149	B6	H	H	H	d.b.	2-benzothiienyl	(±)- <i>cis</i>
150	B6	H	H	H	d.b.		(±)- <i>cis</i>
151	B6	H	H	H	-S-	phenyl	(±)- <i>cis</i>
152	B6	H	H	H	d.b.	1-methyl-2-pyrrolyl	(±)- <i>cis</i>
153	B1a	H	CF ₃	H	d.b.	3,5-di(trifluoromethyl)phenyl	(±)- <i>cis</i>
154	B1a	H	CF ₃	H	d.b.	3,5-di(trifluoromethyl)phenyl	(±)- <i>trans</i>

* d.b. means direct bond

C. Pharmacological examples

Example C.1 : Antagonism of substance-P induced relaxation of the pig coronary

5 arteries

Segments of coronary arteries taken from pigs (killed by injection of an overdose of sodium pentobarbital) were inverted and mounted for recording of isometric tension in organ baths (volume 20 ml) with the endothelium at the outside. The preparations were bathed in Krebs - Henseleit solution. The solution was kept at 37 °C and gassed with a mixture of O₂ / CO₂ (95/5). After stabilisation of the preparations, prostaglandin F_{2α} (10⁻⁵ M) was administered to induce a contraction. This was repeated until contractile responses became stable. Then prostaglandin F_{2α} was again administered and substance P (3x10⁻¹⁰ M and 10⁻⁹ M cumulatively) was added. Substance P induced endothelium dependent relaxations. After washing away the agonists, a known concentration of a compound of formula (I) was added. After an incubation period of

30 minutes, prostaglandin F_{2α} (10⁻⁵ M) and the same concentrations of substance P as described above were again administered in the presence of the compound to be tested. Relaxations caused by substance P were expressed as relaxations under control conditions, and percentage inhibition (% inhibition) of the response to 10⁻⁹ M substance P was taken as a measure of the antagonistic activity of the compound to be tested. The results for the compounds of the present invention at a certain test concentration are listed in table 6

Table 6

Comp. No.	Concentration test compound	% inhibition	Comp. No.	Concentration test compound	% inhibition
1	3 x 10 ⁻⁷	70.7	61	3 x 10 ⁻⁹	66.3
2	3 x 10 ⁻⁸	26.3	62	3 x 10 ⁻¹⁰	23.8
3	3 x 10 ⁻⁸	23.5	65	3 x 10 ⁻¹⁰	11.6
4	3 x 10 ⁻⁸	23.5	68	3 x 10 ⁻⁹	21.3
5	3 x 10 ⁻⁸	66.4	70	3 x 10 ⁻⁹	7.2
6	3 x 10 ⁻⁸	70.7	71	3 x 10 ⁻⁹	9.1
7	3 x 10 ⁻⁸	27.8	72	3 x 10 ⁻⁹	40.6
8	3 x 10 ⁻⁸	49.4	73	3 x 10 ⁻⁹	51.3
9	3 x 10 ⁻⁸	70.0	74	3 x 10 ⁻⁹	22.6
10	3 x 10 ⁻⁸	89.2	75	3 x 10 ⁻⁹	68.4
11	3 x 10 ⁻⁸	94.1	76	3 x 10 ⁻⁹	71.3
12	3 x 10 ⁻⁸	6.0	77	3 x 10 ⁻⁹	68.2
13	3 x 10 ⁻⁸	19.4	78	3 x 10 ⁻⁹	40.8
14	3 x 10 ⁻⁸	42.9	79	3 x 10 ⁻⁹	19.4
15	3 x 10 ⁻⁸	69.6	80	3 x 10 ⁻⁸	82.9
17	3 x 10 ⁻⁸	68.3	81	3 x 10 ⁻⁹	93.1
19	3 x 10 ⁻⁸	12.8	82	3 x 10 ⁻⁹	12.5
20	3 x 10 ⁻⁸	22.7	83	3 x 10 ⁻⁹	10.0
21	3 x 10 ⁻⁸	25.3	88	3 x 10 ⁻⁹	68.6
24	3 x 10 ⁻⁸	13.1	91	3 x 10 ⁻⁹	17.6
25	3 x 10 ⁻⁸	28.2	92	3 x 10 ⁻⁹	21.0
26	3 x 10 ⁻⁸	17.6	93	3 x 10 ⁻⁹	7.0
27	3 x 10 ⁻⁸	12.9	96	3 x 10 ⁻⁹	18.4
28	3 x 10 ⁻⁸	36.3	98	3 x 10 ⁻⁹	16.7

Comp. No.	Concentration test compound	% inhibition	Comp. No.	Concentration test compound	% inhibition
29	3×10^{-8}	78.4	101	3×10^{-9}	7.9
32	3×10^{-8}	21.0	102	3×10^{-9}	12.9
33	3×10^{-8}	51.4	103	3×10^{-9}	5.8
34	3×10^{-8}	47.7	105	3×10^{-9}	10.6
35	3×10^{-8}	50.0	106	3×10^{-9}	18.2
36	3×10^{-8}	57.5	107	3×10^{-9}	5.1
37	3×10^{-8}	84.9	109	3×10^{-9}	68.7
39	3×10^{-8}	63.3	110	3×10^{-10}	57.6
40	3×10^{-8}	79.4	111	3×10^{-9}	85.7
41	3×10^{-8}	77.6	112	3×10^{-9}	96.8
42	3×10^{-8}	66.9	113	3×10^{-9}	89.3
43	3×10^{-9}	93.7	114	3×10^{-9}	95.3
44	3×10^{-8}	57.8	115	3×10^{-9}	91.1
45	3×10^{-8}	85.7	116	3×10^{-10}	93.1
46	3×10^{-8}	67.8	117	3×10^{-9}	9.4
47	3×10^{-9}	88.4	118	3×10^{-9}	36.9
48	3×10^{-9}	92.3	121	3×10^{-9}	6.3
49	3×10^{-8}	78.1	124	3×10^{-9}	31.2
50	3×10^{-8}	91.0	125	3×10^{-9}	20.1
51	3×10^{-8}	90.4	128	3×10^{-9}	16.7
52	3×10^{-9}	86.0	129	3×10^{-9}	64.9
53	3×10^{-8}	70.3	131	3×10^{-9}	21.6
54	3×10^{-8}	83.6	134	3×10^{-9}	32.0
55	3×10^{-8}	79.3	138	3×10^{-9}	9.1
56	3×10^{-7}	100	144	3×10^{-9}	16.6
57	3×10^{-7}	43.2	148	3×10^{-10}	12.6
58	3×10^{-8}	91.7	149	3×10^{-10}	9.9
59	3×10^{-9}	80.7	153	3×10^{-9}	43.5
60	3×10^{-9}	72.8	154	3×10^{-9}	95.7

Example C.2 : Antagonism of substance P induced plasma extravasation in guinea-pigs

Plasma extravasation was induced by injection of substance P (2 mg/kg) in the femoral artery of female guinea-pigs. Evans Blue dye (30 mg/kg) was injected simultaneously.

- 5 The test compound or solvent was administered 1 hour prior to substance P injection.

10 minutes after challenge, the animals were checked for blue colouring (a direct measure for plasma extravasation) of the nose, the forepaws, and the conjunctiva. 30 minutes after challenge, the animals were sacrificed by CO₂ gas inhalation and checked for blue colouring of the trachea and the urinary bladder. Doses which actively inhibit substance P-induced plasma extravasation are defined as those doses at which only 1/3 or less of the total surface area of the nose, forepaws, conjunctiva, trachea or urinary bladder are coloured blue by an intensive extravasation. Table 7 lists the lowest active doses (LAD) in mg/kg for the tested compounds.

10 Table 7

Co. No.	LAD (in mg/kg)				
	nose	forepaws	conjunctiva	trachea	urinary bladder
128	2.5	2.5	2.5	10	10
59	2.5	2.5	2.5	10	25
129	10	10	10	10	10
78	10	10	10	10	10
79	10	10	10	10	10
76	10	10	10	10	10
112	2.5	2.5	2.5	2.5	2.5
116	10	10	10	10	2.5
115	10	10	10	10	10
60	10	10	10	10	10
61	10	10	10	10	10
114	0.63	0.63	0.63	2.5	10
80	10	10	10	10	10
81	10	10	10	10	10
43	2.5	2.5	2.5	10	10
47	2.5	2.5	10	40	40
48	2.5	2.5	2.5	10	40
110	10	10	10	10	10
88	> 10	10	10	10	10

D. Composition examples

15 "Active ingredient" (A.I.) as used throughout these examples relates to a compound of formula (I) a pharmaceutically acceptable addition salt, a stereochemically isomeric form thereof or a *N*-oxide form thereof.

Example D.1 : ORAL SOLUTION

Methyl 4-hydroxybenzoate (9 g) and propyl 4-hydroxybenzoate (1 g) were dissolved in boiling purified water (4 l). In 3 l of this solution were dissolved first 2,3-dihydroxybutanedioic acid (10 g) and thereafter A.I (20 g). The latter solution was
5 combined with the remaining part of the former solution and 1,2,3-propanetriol (12 l) and sorbitol 70% solution (3 l) were added thereto. Sodium saccharin (40 g) were dissolved in water (500 ml) and raspberry (2 ml) and gooseberry essence (2 ml) were added. The latter solution was combined with the former, water was added q.s. to a volume of 20 l providing an oral solution comprising 5 mg of the active ingredient per teaspoonful (5
10 ml). The resulting solution was filled in suitable containers.

Example D.2 : FILM-COATED TABLETS**Preparation of tablet core**

A mixture of A.I. (100 g), lactose (570 g) and starch (200 g) was mixed well and
15 thereafter humidified with a solution of sodium dodecyl sulfate (5 g) and polyvinylpyrrolidone (10 g) in water (200 ml). The wet powder mixture was sieved, dried and sieved again. Then there was added microcrystalline cellulose (100 g) and hydrogenated vegetable oil (15 g). The whole was mixed well and compressed into tablets, giving 10.000 tablets, each containing 10 mg of the active ingredient.

Coating


To a solution of methyl cellulose (10 g) in denaturated ethanol (75 ml) there was added a solution of ethyl cellulose (5 g) in CH_2Cl_2 (150 ml). Then there were added CH_2Cl_2 (75 ml) and 1,2,3-propanetriol (25 ml). Polyethylene glycol (10 g) was molten and dissolved in CH_2Cl_2 (75 ml). The latter solution was added to the former and then there
25 were added agnesium octadecanoate (2.5 g), polyvinylpyrrolidone (5 g) and concentrated colour suspension (30 ml) and the whole was homogenated. The tablet cores were coated with the thus obtained mixture in a coating apparatus.

Example D.3 : INJECTABLE SOLUTION

30 Methyl 4-hydroxybenzoate (1.8 g) and propyl 4-hydroxybenzoate (0.2 g) were dissolved in boiling water (500 ml) for injection. After cooling to about 50°C there were added while stirring lactic acid (4 g), propylene glycol (0.05 g) and the A.I. (4 g). The solution was cooled to RT and supplemented with water for injection q.s. ad 1 l, giving a solution comprising 4 mg/ml of A.I.. The solution was sterilized by filtration
35 and filled in sterile containers.

Claims

1. A compound of formula



a *N*-oxide form, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein

n is 0, 1 or 2;

m is 1 or 2, provided that if *m* is 2, then *n* is 1;

p is 0, 1 or 2;

=Q is =O or =NR³;

10 X is a covalent bond or a bivalent radical of formula -O-, -S-, -NR³-;

R¹ is Ar¹; Ar¹C₁₋₆alkyl or di(Ar¹)C₁₋₆alkyl, wherein each C₁₋₆alkyl group is optionally substituted with hydroxy, C₁₋₄alkyloxy, oxo or a ketalized oxo substituent of formula -O-CH₂-CH₂-O- or -O-CH₂-CH₂-CH₂-O-;


R² is Ar²; Ar²C₁₋₆alkyl; Het or HetC₁₋₆alkyl;

15 R³ is hydrogen or C₁₋₆alkyl;

R⁴ is hydrogen; C₁₋₄alkyl; C₁₋₄alkyloxyC₁₋₄alkyl; hydroxyC₁₋₄alkyl; carboxyl; C₁₋₄alkyloxycarbonyl or Ar³;


R⁵ is hydrogen; hydroxy; Ar³; Ar³C₁₋₆alkyloxy; di(Ar³)C₁₋₆alkyloxy; Ar³C₁₋₆alkylthio; di(Ar³)C₁₋₆alkylthio; Ar³C₁₋₆alkylsulfoxy;

20 di(Ar³)C₁₋₆alkylsulfoxy; Ar³C₁₋₆alkylsulfonyl; di(Ar³)C₁₋₆alkylsulfonyl; -NR⁷R⁸; C₁₋₆alkyl substituted with -NR⁷R⁸; or a radical of formula



(a-1)

or



(a-2)

wherein R⁷ is hydrogen; C₁₋₆alkyl; pyridinyl or Ar³;

R⁸ is hydrogen; C₁₋₆alkyl; Ar³C₁₋₆alkyl; di(Ar³)C₁₋₆alkyl;

25 imidazolyl substituted with Ar³, C₁₋₆alkyl or Ar³C₁₋₆alkyl; benzoxazolyl or benzothiazolyl;

R⁹ is hydrogen; hydroxy; C₁₋₆alkyl; C₁₋₆alkyloxy; Ar³;

Ar³C₁₋₆alkyl; di(Ar³)C₁₋₆alkyl; amino; mono- or di(C₁₋₆alkyl)amino; imidazolyl; imidazolyl substituted with


Ar³, C₁-6alkyl or Ar³C₁-6alkyl; pyrrolidinyl; piperidinyl;
 homopiperidinyl; morpholinyl or thiomorpholinyl;
 R¹⁰ is hydrogen or C₁-6alkylcarbonyl;
 R¹¹ is hydrogen; halo or mono-, di- or tri(halo)methyl;
 Y is Y¹ or Y², wherein
 Y¹ is a covalent bond; C₁-6alkanediyl; -NR⁷- or
 -C₁-6alkanediyl-NR⁷-; or
 Y² is -O-, provided that R⁹ is other than hydroxy or
 C₁-6alkyloxy;

- 5 R⁴ and R⁵ may also be taken together to form a bivalent radical of formula -
 O-CH₂-CH₂-O- or -C(=O)-NR³-CH₂-NR⁷-;
 R⁶ is hydrogen; hydroxy; C₁-6alkyloxy; C₁-6alkyl or Ar³C₁-6alkyl;
 Ar¹ is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently
 selected from halo, C₁-4alkyl, haloC₁-4alkyl, cyano, aminocarbonyl,
 C₁-4alkyloxy or haloC₁-4alkyloxy;
 Ar² is naphthalenyl; phenyl; phenyl substituted with 1, 2 or 3 substituents each
 independently selected from hydroxy, halo, cyano, nitro, amino, mono- or
 di(C₁-4alkyl)amino, C₁-4alkyl, haloC₁-4alkyl, C₁-4alkyloxy,
 haloC₁-4alkyloxy, carboxyl, C₁-4alkyloxycarbonyl, aminocarbonyl and mono-
 or di(C₁-4alkyl)aminocarbonyl;
 Ar³ is phenyl or phenyl substituted with 1, 2 or 3 substituents selected from halo,
 hydroxy, amino, nitro, aminocarbonyl, C₁-6alkyl, haloC₁-6alkyl or
 C₁-6alkyloxy; and
 Het is a monocyclic heterocycle selected from pyrrolyl, pyrazolyl, imidazolyl,
 furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl,
 pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocycle selected from
 quinolinyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl,
 benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl and
 benzothienyl; each monocyclic and bicyclic heterocycle may optionally be
 substituted on a carbon atom by 1 or 2 substituents selected from halo,
 C₁-4alkyl or mono-, di- or tri(halo)methyl.
2. A compound as claimed in claim 1 wherein R⁸ is hydrogen; C₁-6alkyl; Ar³C₁-
 6alkyl; di(Ar³)C₁-6alkyl; benzoxazolyl or benzothiazolyl; R⁹ is hydrogen;
 hydroxy; C₁-6alkyl; C₁-6alkyloxy; Ar³; Ar³C₁-6alkyl; di(Ar³)C₁-6alkyl; amino;
 mono- or di(C₁-6alkyl)amino; pyrrolidinyl; piperidinyl; homo-piperidinyl;
 morpholinyl or thiomorpholinyl; and Het is a monocyclic heterocycle selected

- from pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocycle selected from quinolinyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl and benzothienyl; each monocyclic and bicyclic heterocycle may optionally be substituted on a carbon atom by 1 or 2 substituents selected from halo, C₁₋₄alkyl or mono-, di- or tri(halo)methyl.
- 5
3. A compound as claimed in claim 1 or 2 wherein R¹ is Ar¹C₁₋₆alkyl, R² is phenyl substituted with 2 substituents selected from methyl or trifluoromethyl, X is a covalent bond and =Q is =O.
- 10
4. A compound as claimed in any one of claims 1 to 3 wherein m, n and p are 1.
- 15
5. A compound as claimed in any one of claims 1 to 4 wherein p is 1; R⁴ is hydrogen; C₁₋₄alkyloxyC₁₋₄alkyl, phenyl or phenyl substituted with halo; R⁵ is phenyl; amino substituted with phenyl or substituted imidazolyl; or phenyl substituted with halo; or R⁵ is a radical of formula (a-1) wherein Y is Y¹ or Y² wherein Y¹ is a covalent bond, -NR⁷- or -CH₂-NR⁷-; wherein R⁷ is hydrogen or phenyl optionally substituted with halo; Y² is -O-; R⁹ is C₁₋₆alkyl, C₁₋₆alkyloxy, pyrrolidinyl, phenylC₁₋₆alkyl, imidazolyl substituted with phenylC₁₋₆alkyl or Ar³; or R⁵ is a radical of formula (a-2) wherein R¹⁰ is hydrogen or C₁₋₆alkylcarbonyl; R¹¹ is hydrogen; or R⁴ and R⁵ are taken together to form a bivalent radical of formula -C(=O)-NR³-CH₂-NR⁷- wherein each R⁷
- 20
- independently is selected from hydrogen or phenyl; and R⁶ is hydrogen.
- 25
6. A compound as claimed in claim 1 wherein the compound is
- 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]-2-(phenylmethyl)piperidine;
- 30
- 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-[4-phenyl-4-(1-pyrrolidinylcarbonyl)-1-piperidinyl]piperidine;
- N-[[1-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-4-phenyl-4-piperidinyl]methyl]acetamide; or
- 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-
- 35
- 8-yl]-2-(phenylmethyl)piperidine;
- 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-phenyl-4-(1-pyrrolidinylcarbonyl)-1-piperidinyl]-2-[[4-(trifluoromethyl)phenyl]methyl]piperidine; and


1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-difluorophenyl)methyl]-4-[4-phenyl-4-(1-pyrrolidinylcarbonyl)-1-piperidinyl]piperidine; a stereoisomeric form, or a pharmaceutically acceptable acid addition salt thereof.

- 5 7. A compound as claimed in any one of claims 1 to 6 for use as a medicine.
8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as active ingredient a therapeutically effective amount of a compound as claimed in any one of claims 1 to 6.
- 10 9. A process of preparing a composition as claimed in claim 8, characterized in that a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as claimed in any one of claims 1 to 6.
- 15 10. A process of preparing a compound as claimed in claim 1, characterized by a) reductively *N*-alkylating an intermediate of formula (III) wherein R⁴, R⁵ and R⁶ are defined as in claim 1, with an intermediate of formula (II)




wherein R¹, R², X, =Q, n, m and p are defined as in claim 1, in a reaction-inert solvent, in the presence of a reducing agent and optionally in the presence of a suitable catalyst;

b) reacting an intermediate of formula (IV) wherein R², X and =Q are defined as in claim 1 and W¹ is an appropriate leaving group with an intermediate of formula (V)



wherein wherein R¹, R⁴, R⁵, R⁶, X, =Q, n, m and p are defined as in claim 1, in a reaction-inert solvent and in the presence of a suitable base;

c) reacting a piperidinone derivative of formula (VI) wherein R¹, R², R⁶, X, =Q, n, m and p are defined as in claim 1, with an intermediate of formula (VII)



wherein M is an appropriate organometallic part and R^{4'} is the same as R⁴ as defined in claim 1 but other than hydrogen;

- 5 and, if desired, converting compounds of formula (I) into each other following art-known transformations; and further, if desired, converting the compounds of formula (I), into a therapeutically active non-toxic acid addition salt by treatment with an acid, or conversely, converting the acid addition salt form into the free base by treatment with alkali; and, if desired, preparing stereochemically isomeric forms or *N*-oxide forms thereof.

INTERNATIONAL SEARCH REPORT

In: National Application No
PCT/EP 96/05883

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D211/46 C07D211/52 C07D211/58 C07D401/14
C07D417/14 C07D401/06 C07D491/10 C07D471/10 C07D405/14
C07D409/14 A61K31/445

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 93 14083 A (JANSSEN) 22 July 1993 see the whole document ---	1-10
A	EP 0 151 824 A (JANSSEN) 21 August 1985 cited in the application see the whole document -----	1-10

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- * "A" document defining the general state of the art which is not considered to be of particular relevance
- * "E" earlier document but published on or after the international filing date
- * "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- * "O" document referring to an oral disclosure, use, exhibition or other means
- * "P" document published prior to the international filing date but later than the priority date claimed

- * "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- * "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- * "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * "&" document member of the same patent family

Date of the actual completion of the international search

7 April 1997

Date of mailing of the international search report

11.04.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Kissler, B

INTERNATIONAL SEARCH REPORT

(Information on patent family members)

In. tional Application No

PCT/EP 96/05883

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9314083 A	22-07-93	AU 3347493 A ZA 9300144 A	03-08-93 08-07-94
EP 151824 A	21-08-85	US 4588722 A AU 575612 B AU 3736385 A BG 47033 A CA 1246070 A JP 60174778 A SU 1400509 A	13-05-86 04-08-88 01-08-85 16-04-90 06-12-88 09-09-85 30-05-88

THIS PAGE BLANK (USPTO)